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ABSTRACT
Clinical research examining the role of hematopoietic stem cell transplantation (HSCT) in the therapy of acute
myelogenous leukemia (AML) in adults is presented and critically evaluated in this systematic evidence-based
review. Specific criteria were used for searching the published literature and for grading the quality and strength
of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the
evidence are presented in Table 3, entitled Summary of Treatment Recommendations Made by the Expert Panel for
Adult Acute Myelogenous Leukemia, and were reached unanimously by a panel of AML experts. The identified
priority areas of needed future research in adult AML include: (1) What is the role of HSCT in treating patients
with specificmolecular markers (eg, FLT3,NPM1,CEBPA, BAALC,MLL,NRAS, etc.) especially in patients with
normal cytogenetics? (2)What is the benefit of usingHSCT to treat different cytogenetic subgroups? (3)What is
the impact on survival outcomes of reduced intensity or nonmyeloablative versus conventional conditioning in
older (.60 years) and intermediate (40-60 years) aged adults? (4) What is the impact on survival outcomes of
unrelated donor HSCT vesus chemotherapy in younger (\40 years) adults with high risk disease?
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The American Society for Blood and Marrow
Transplantation (ASBMT), in 1999, began an initiative
to sponsor evidence-based reviews of the scientific and
medical literature for the use of blood and marrow
transplantation in the therapy of selected diseases.
The steering committee that was convened to oversee
the projects invited an independent panel of disease-
specific experts to conduct each review. Five previousreviews have been published in Biology of Blood and
Marrow Transplantation: Diffuse Large B Cell Non-
HodgkinLymphoma [1],MultipleMyeloma (MM) [2],
Pediatric Acute Lymphocytic Leukemia (ALL) [3],
Adult ALL [4], and Pediatric AcuteMyeloid Leukemia
(AML) [5].
The following is the sixth review to result from this
initiative. Its goals are to assemble and critically evaluate
all of the evidence regarding the role of hematopoietic137
138 D. M. Oliansky et al.Table 1. Grading the Quality of Design and Strength of Evidence
Levels of evidence
111 High-qualitymeta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTswith a very low risk of bias
11 Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
12 Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
211 High-quality systematic reviews of case-controlled or cohort studies High-quality case-controlled or cohort studies with
a very low risk of confounding, bias, or chance and a high probability that the relationship is causal
21 Well-conducted case-controlled or cohort studies with a low risk of confounding, bias, or chance and a moderate
probability that the relationship is causal
22 Case-controlled or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship
is not causal
3 Nonanalytic studies, for example, case reports, case series
4 Expert opinion
Reprinted with permission from Harbour R, Miller J. A new system for grading recommendations in evidence-based guidelines. Br Med J.
2001;323:334-336.stem cell transplantation (HSCT) in the therapy of
adult ($15 years) patients with AML, make treatment
recommendations based on the available evidence, and
identify areas of needed research.
LITERATURE SEARCH METHODOLOGY
PubMed and Medline, the Web sites developed by
the National Center of Biotechnology Information at
the National Library of Medicine of the National In-
stitutes of Health, were searched August 8, 2006, using
the search terms ‘‘acute myeloid leukemia’’ or ‘‘acute
myelogenous leukemia’’ and ‘‘transplant,’’ limited to
human trials, English language, and a publication
date of 1990 or later. An updated search was conducted
in early May, 2007, limited to August 9, 2006, to April
30, 2007. Manuscripts were excluded if they were pub-
lished before 1990, included\50 AML patients, were
not peer reviewed, were editorials, letters to the editor,
Phase I (dose-escalation or dose-finding) studies, re-
views, consensus conference papers, practice guide-
lines, laboratory studies with no clinical correlates,
did not focus on an aspect of therapy with HSCT for
the treatment of adult AML, or if .50% of the study
population was \15 years and the results were not
stratified by age. In addition, for a manuscript to be in-
cluded, a minimum of 70% of study subjects had to be
AML patients, or study results had to be stratified bydisease. Abstracts and presentations at national or in-
ternational meetings were not included as evidence
in this review for reasons previously described [3].
QUALITATIVE AND QUANTITATIVE GRADING
OF THE EVIDENCE
The hierarchy of evidence, including a grading sys-
tem for the quality and strength of the evidence, and
strength of each treatment recommendation, was es-
tablished and published as an editorial policy state-
ment in Biology of Blood and Marrow Transplantation in
2005 [6]. Tables 1 and 2 are reprinted from the policy
statement and define criteria used to grade the studies
included in this review and to grade the treatment rec-
ommendations. Study design, including sample size,
patient selection criteria, duration of follow-up, and
treatment plan also were considered in evaluating the
studies. Several multicenter clinical trials were de-
signed to biologically assign patients to a treatment
arm based on the availability of a donor (‘‘biologic
allocation’’). These studies of allogeneic (allo) HSCT
versus chemotherapy are therefore graded as level
‘‘2’’ evidence, not level ‘‘1,’’ because they are not statis-
tically randomized controlled trial designs. Autolo-
gous (auto) HSCT versus chemotherapy studies were
graded as level ‘‘1’’ evidence if the study design in-
cluded a statistically randomized controlled trial.Table 2. Grading the Strength of the Treatment Recommendation
Grades of recommendation
A At least one meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 111, and directly applicable
to the target population; or a systematic review of RCTs or a body of evidence consisting principally of studies rated as
11, directly applicable to the target population, and demonstrating overall consistency of results
B A body of evidence including studies rated as 211, directly applicable to the target population, and demonstrating overall
consistency of results; or extrapolated evidence from studies rated as 111 or 11
C A body of evidence including studies rated as 21, directly applicable to the target population and demonstrating overall
consistency of results; or extrapolated evidence from studies rated as 211
D Evidence level 3 or 4; or extrapolated evidence from studies rated as 21
Reprinted with permission from Harbour R, Miller J. A new system for grading recommendations in evidence-based guidelines. Br Med J.
2001;323:334-336.
The Role of Cytotoxic Therapy with HSCT 139Table 3. Summary of Treatment Recommendations Made by the Expert Panel for Adult Acute Myelogenous Leukemia
Indication for
HSCT
Treatment
Recommendation
Grade*
Highest
Level of
Evidence†
Reference
No.h Treatment Recommendation Comments
TRANSPLANTATION VERSUS CHEMOTHERAPY
Autologous (Auto) SCT versus Chemotherapy (Chemo) in CR1
Induction 1 intensive
consolidation chemo
(ICC), then ICC
versus auto
A 11 [9, 10] Based on the survival data presented, there is
no significant advantage of auto-SCT
over chemotherapy. Most of the data reflect
outmoded treatment strategies (i.e., BM versus
PBSC; maintenance therapy pre-SCT, etc.);
studies using modern technologies may effect
outcomes to an unknown extent.
Induction 1 ICC, then
no further Tx versus
auto
B 12 [13,14] Same as above
Induction, then ICC
versus auto
B 11 [16] Same as above
Allogeneic (Allo) SCT versus Chemo in CR1
Myeloablative Allo-
SCT versus chemo
A 11 [18] There is a survival advantage for allo-SCT versus
chemotherapy for patients\55 years with high
risk cytogenetics. There is insufficient evidence
to routinely recommend allo-SCT for patients
with intermediate risk cytogenetics, although
this is a reasonable strategy. There is no survival
advantage for allo-SCT in patients\55 years
with low risk cytogenetics. There are insufficient
data to make a recommendation on the use of
myeloablative regimens for patients .55 years.
Reduced-intensity
conditioning (RIC)
Allo versus
chemo
No
recommendation
22 [26] There are insufficient data to make a
recommendation.
SCT versus Chemo in CR2
Allo-SCT versus
chemo in CR2
D 4 [27] Based on expert opinion and clinical practice, it
is recommended that patients in CR2 receive an
allo-SCT if there is an available donor;
otherwise, an auto-SCT is
recommended.
TRANSPLANTATION TECHNIQUES
Allogeneic versus
Autologous SCT
B 211 [28,29] Based on data and expert opinion, an HLA-
matched related donor (MRD) allo-SCT is
recommended over auto-SCT, if an MRD is
available. There are insufficient data to make
a recommendation for matched unrelated
donor (MUD) allo-SCT versus auto-SCT.
These studies do not reflect modern techniques
in supportive care, stem cell source, or the use
of molecular HLA typing (for the MUD studies).
Autologous SCT
PBSCT versus BMT C 21 [37-39] Based on data and clinical practice, PBSCT is
recommended due to improvement in safety
and early mortality. However, long-term
outcomes have not been studied prospectively;
therefore, the impact of PBSCTon OS is
unknown.
Unpurged versus
purgedY
C 21 [40-42] There is no evidence of a survival advantage
with purged BMT. There are insufficient data
to make a recommendation for purging of
PBSCT.
Tandem versus
single
No
recommendation
2- [43] There are insufficient data to make a
recommendation.
Allogeneic SCT
Related versus
unrelated
C 21 [55,56] MRD allo-SCT is recommended if available. If
a MRD is not available, a MUD allo-SCT may
provide equivalent outcomes.
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Indication for
HSCT
Treatment
Recommendation
Grade*
Highest
Level of
Evidence†
Reference
No.h Treatment Recommendation Comments
T cell replete
versus
T cell depleted
B 11 [57] There is no evidence of a survival advantage
with T cell-depleted grafts.
PBSCT versus BMT C 211 [59] For high-risk disease, allo-PBSCT is recommended
over BMT. For low-risk disease, allo-PBSCTand
BMT have equivalent outcomes. There are
insufficient data to make a recommendation on
stem cell source for MUD allo-SCT.
Therapy Regimens
Auto-SCT—
Comparison of 2 or
more high-dose
therapy regimens
C 21 [77 - 78] There is no evidence of a survival advantage
with any one high-dose therapy regimen.
Allo-SCT—
Comparison of 2 or
more myeloablative
conditioning regimens
B 11 [79 - 80] There is no significant survival advantage with
any one myeloablative conditioning regimen.
Studies of late effects may change this
recommendation. If a TBI-containing
conditioning regimen is used, fractionated
rather than single-dose TBI is recommended.
Allo-SCT—
Use of RIC
regimens
No
recommendation
211 [86] There are insufficient data to make a
recommendation. The use of RIC is dependent
on patient characteristics such as age,
comorbidities, and cytogenetic risk.
HSCT indicates hematopoietic stem cell transplantation; CR, complete remission; ICC, intensive consolidation chemotherapy; PBSC, periph-
eral blood stem cell; PBSCT, peripheral blood stem cell transplantation; BM, bone marrow; BMT, bone marrow transplantation; RIC, re-
duced-intensity conditioning; HLA, human leukocyte antigen; MRD, matched-related donor; MUD, matched-unrelated donor; TBI, total
body irradiation; OS, overall survival.
*Definitions: Grade of Recommendation (Table 2): (A) At least one meta-analysis, systematic review, or randomized controlled trial (RCT)
rated as 111, and directly applicable to the target population; or a systematic review of RCTs or a body of evidence consisting principally of
studies rated as 11, directly applicable to the target population, and demonstrating overall consistency of results. (B) A body of evidence including
studies rated as 211, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from
studies rated as 111 or 11. (C) A body of evidence including studies rated as 21, directly applicable to the target population and demonstrating
overall consistency of results; or extrapolated evidence from studies rated as 211; (D) Evidence level 3 or 4; or extrapolated evidence from studies
rated as 21
†Definitions: Levels of Evidence (Table 1): 111 High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or
RCTs with a very low risk of bias. 11Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias. 12Meta-
analyses, systematic reviews of RCTs, or RCTswith a high risk of bias. 211High-quality systematic reviews of case-control or cohort studies; or
High-quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is
causal. 21Well-conducted case control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the
relationship is causal; 22Case-control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship
is not causal. 3 Nonanalytic studies, for example, case reports, case series. 4 Expert opinion.
hThe references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence
described in the review.
YPurging: Techniques to remove tumor, either by negative or positive selection.Clinical studies are described with enough detail to
give a concise summary of study design, sample size,
and eligibility criteria.
All data in the text and tables were abstracted from
the original manuscripts by the first author (D.O.),
then double checked for accuracy and clarity by 2 other
authors (T.H. and P.L.M.) and 1 additional reviewer
(see Acknowledgments). In some articles there were
discrepancies within the data reported and, in these
cases, the data most consistent with the text of the
article were presented in this review. The last author
(T.H.) takes responsibility if errors remain. Appendix
A lists the common abbreviations used in this review.TREATMENT RECOMMENDATIONS
The strength of this review is the detail conveyed
in the text about the study designs and the presentation
of the outcomes in the summary tables included in
each major section. Table 3 contains the summary of
treatment recommendations made by the adult AML
expert panel.
FORMATOF THE REVIEW
Evidence is taken from self-described studies of
adult populations that included patients $15 years of
age. In each section of this review, the highest quality
The Role of Cytotoxic Therapy with HSCT 141studies are presented first; studies of equal quality are
presented in descending order by sample size. The
design of each study is described in the text and, unless
otherwise noted, the accompanying table in each
section presents the outcomes for each study.
HSCT VERSUS CHEMOTHERAPY IN ADULT AML
Table 4 presents a summary of the outcomes for
each of the studies in this section. Of the 10 studies in-
vestigating auto-HSCT versus chemotherapy, 5 found
a significant difference in disease-free survival (DFS),
relapse-free survival (RFS), or leukemia-free survival
(LFS), and 2 studies found a significant difference in
overall survival (OS). Of the 14 studies that examined
allo-HSCT versus chemotherapy 6 auto-HSCT, 7
reported a statistically significant difference in DFS,
LFS, or event-free survival (EFS), and 4 studies found
a significant difference in OS. Table 5 presents a sum-
mary of the treatment schema used in the auto-HSCT
versus chemotherapy studies.
Autologous SCT versus Chemotherapy in First
Complete Remission (CR1)
Levi et al. [7] and Nathan et al. [8] each presented
the results of meta-analyses of the same 6 randomized
controlled studies comparing auto bone marrow trans-
plantation (BMT) to chemotherapy or no further treat-
ment. The methods and results of these 2 studies were
comparable; hence, only 1 study [7] is summarized
here. Study requirements for potential inclusion in
the Levi et al. meta-analysis were: randomization to
auto-BMT in 1 arm and chemotherapy or no further
treatment in the second arm, study sample aged 15-
56 years, only AML patients, and data analysis based
on intention-to-treat (ITT).Of 4410 recruited patients
across the 6 studies, 3220 (73%) achieved CR1, and
1044 (23% of recruited patients) were randomized to
receive an auto-BMT or chemotherapy only (or no
further therapy). Of these, 835 (80%) received the
intended treatment, 360 in the auto-BMT arm and
475 in the control arm. The reasons for nontransplant
included recurrence of disease, toxicity of prior treat-
ment, and patient refusal to have a transplant. Risk of
dying (death rate) and risk of relapse or death (event
rate) were determined for the auto-BMT and other
arm. Relative risks (RR) and 95% confidence intervals
(CI) of death and events rates were calculated for each
study, fromwhich a combined estimate of each rate was
calculated across the 6 studies. Cytogenetic data from
the studies were not considered in the meta-analysis.
Figure 1 compares the RR of relapse or death between
the auto-BMT and control groups.
Treatment schema I: induction 1 intensive consolidation
chemo (ICC), then auto-SCT versus additional ICC. Zittoun
et al. [9] presented the results of the European Organi-
zation for Research and Treatment of Cancer(EORTC) andGruppo ItalianoMalattie Ematologiche
Maligne dell’Adulto (GIMEMA) Leukemia Coopera-
tiveGroups prospective study of 990 adult (11-59 years;
.90% were $15 years) patients with previously un-
treated AML, comparing the outcomes of postremis-
sion allo-BMT, auto-BMT, and chemotherapy. Some
centers from the GIMEMA group excluded patients
with acute promyelocytic (M3) leukemia (APL). Of
the 990 enrolled patients, 36 (4%)were ineligible (inad-
equate diagnosis [n5 19]; other exclusion criteria [n5
17]) and 13 (1%) hadmissing data, leaving a total of 941
(95%) evaluable patients. A total of 623 (66%) patients
achieved CR1. A human leukocyte antigen (HLA)-
matched sibling donor was available for 230 patients,
and 168 (27% of CR1 patients) were assigned to allo-
BMT. Of the remaining patients, 254 (41% of CR1 pa-
tients) were randomized to either auto-BMT (n5 128)
or a second course of chemotherapy (n 5 126). There
were no significant differences among the 3 treatment
groups by age, white blood cell (WBC) count at diagno-
sis, French-American-British (FAB) AML classifica-
tion, number of induction cycles needed to reach
Figure 1. Relative risk (RR) of relapse or death rate comparing autol-
ogous BMT with the control arm. (Reprinted with permission; [7].)
142 D. M. Oliansky et al.CR1, or cytogenetic group. The median times from
CR1 to the initiation of postremission therapy were
10, 14, and 15 weeks for the chemotherapy, auto-
BMT, and allo-BMT groups, respectively (P\ .001).
Actual receipt of intended therapy was as follows: allo-
BMT, n 5 144 (86%), auto-BMT, n 5 95 (74%), and
chemotherapy, n 5 104 (83%). Outcome analyses
were on an ITT basis.
Reiffers et al. [10] presented the outcomes of 204
adults (15-55 years) with de novo AML enrolled in the
prospective, multicenter, French BGMT 87 trial
comparing allo-BMT, auto-SCT, and ICC. Of 204
patients, 162 (79.4%) achieved CR1. Between CR1
andconsolidation, 26patientswere excluded for the fol-
lowing reasons: fungal infection (n5 8), early leukemic
relapse (n5 5), cardiac contraindications for anthracy-
cline administration or intensive treatment (n5 4), en-
cephalitis (n5 3), persistent cytopenia (n5 2), refusal of
further treatment (n5 2), and hepatitis (n5 2).One pa-
tient who underwent syngeneic BMTwas also excluded
from the analyses. Of the remaining 135 patients, 36
were #45 years of age with an HLA-identical sibling
donor and were assigned to allo-BMT. Of these, 33
(92%) actually received the assigned treatment. The
99 patients who did not meet the inclusion criteria for
allo-BMT (39 were .45 years; 60 were #45 years,
but with no HLA-identical sibling donor) received in-
tensive chemotherapy, then, while still in CR (n5 77),
were randomly assigned to either auto-SCT (n5 39) or
maintenance chemotherapy (n 5 38). ITT analyses
compared the outcomes between the donor (n 5 39)
and no donor (n 5 60) groups and the randomized
auto-SCT and chemotherapy groups, in addition to
a non-ITT analysis by actual treatment (allo-BMT,
n5 33; auto-SCT, n5 33; and chemotherapy, n5 38).
Median time from CR1 to allo-BMT was 56 days
(range: 42-142 days). The patients in the donor/no
donor groups were similar with regard to sex, WBC
count at diagnosis, and FAB classification. The rate of
high-risk cytogenetic abnormalities was higher in the
donor group than the no donor group, but the differ-
ence was not statistically significant (P 5 .17). Of the
39 patients assigned to auto-SCT, 33 underwent either
transplant with unpurged bone marrow (n 5 16) or
peripheral blood stem cells (PBSC). There were no
significant differences in patient characteristics be-
tween the auto-SCT and maintenance chemotherapy
groups.
Harousseau et al. [11] reported the results of 535
adult (15-50 years) patients enrolled in the Groupe
Ouest Est Leucemies Aigue¨s Myeloblastiques (GOE-
LAM) study comparing the outcomes of allo-BMT,
auto-BMT, and ICC. Of the 535 patients, 18 were
considered ineligible because of inadequate diagnosis
(n 5 9), age (n 5 7), or other reasons (n 5 2). In
addition, 13 patients were not evaluable because of
death (n 5 4), major protocol violation (n 5 5), orwrong randomization (n5 4). Of the 504 evaluable pa-
tients, 367 (73%) achieved CR1. Patients#40 years of
age with an HLA-identical sibling were assigned to
allo-BMT (n 5 88). All other patients received a first
course of ICC. The allo-BMT patients were compared
to a subset of 134 patients#40 years of age, without an
HLA-identical sibling, who had received a first course
of ICC. There were no significant differences in
patient characteristics between these 2 groups except
in cytogenetic risk group: intermediate and unfavor-
able cytogenetics were less common in the allo-BMT
group. The median interval between CR1 and allo-
BMT was 68 days. All patients who received a first
course of ICC were randomly assigned to either a sec-
ond course of ICC (n5 78) or an unpurged auto-BMT
(n 5 86). Analyses were on an ITT basis. Of 367
patients who achieved CR1, 219 (59.5%) received
the planned postremission treatment (73 allo-BMT,
75 auto-BMT, and 71 ICC). Multivariate analyses
considered the impact of FAB type, WBC count at
diagnosis, and cytogenetic risk group on outcomes.
Miggiano et al. [12] reported the results of 89
adults (15-59 years) with AML in late CR1 treated at
a single center in Italy. Three patients had antecedent
myelodysplastic syndrome (MDS) and 1 patient had
therapy-related AML. Of the 89 patients, 51 (57%)
received an auto-BMT. Median time from CR1 to
auto-BMT was 8 months. The remaining 38 patients,
who served as a nonrandomized control group, were
not transplanted because of poor prognostic factors
(n 5 23), severe toxicity after induction therapy (n 5 8),
patient refusal (n 5 4), or logistic difficulties (n 5 3).
The 2 groups differed significantly in age and FAB
subtype. There were no significant differences bet-
ween the therapy groups by sex, type of AML (de
novo versus secondary), or WBC count at diagnosis.
Treatment schema II: induction 1 ICC, then auto-SCT ver-
sus no further treatment. Burnett et al. [13] presented the
results of 381 adult (74%were 15-55 years) patients en-
rolled in the UK Medical Research Council (MRC)
AML-10 trial who were randomized to receive either
auto-BMT (n5 190) or no further treatment (n5 191)
after ICC.The trial was open to patients with de novo or
secondary AML or refractory anemia. A total of 1966
patients were enrolled in the trial, of which 1509
(77%) achieved CR1. Of these, 508 were not eligible
for randomization: 378 had a matched sibling donor,
60 relapsed, and 70 died in remission. Of the 1001
patients eligible for randomization, 620 (62%) were
not randomized because of patient or physician prefer-
ence for an auto-BMT (n5 79) or no further treatment
(n5 481), or for unknown reasons (n5 60). The auto-
BMT and no further treatment groups were similar in
patient characteristics, including age, sex,WBC count,
FAB type, number of cycles needed to achieve CR1,
type of AML, and cytogenetic risk group. Of the 190
patients randomized to auto-BMT, 126 (66%) actually
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patients randomized to no further treatment actually
received an auto-BMT. Reasons for noncompliance
with the allocated treatment included death (n 5 7)
or relapse (n5 11), patient refusal (n 5 20), clinical
decision (n 5 16), and other (n 5 7) or unknown
reasons (n 5 3). Outcome comparisons were by ITT,
with adjustment for cytogenetic risk group.
Breems et al. [14] presented the results of 646 adult
(\60 years) patients with AML enrolled in the Dutch-
Belgian Haemato-Oncology Cooperative Group
(HOVON) and Swiss Group for Clinical Cancer Re-
search (SAKK) trial comparing auto-BMT versus no
further treatment. Of the 646 enrolled, 425 (66%) pa-
tients achieved CR1. Eighty-one patients underwent
an allo-SCT and were not included in the analysis.
An additional 214 patients were deemed ineligible for
randomization because of patient refusal (n5 81), early
relapse (n 5 54), excessive toxicity (n 5 27), or not
meeting inclusion criteria (n5 26), leaving 130 patients
to be randomized between auto-BMT (n5 66) and no
further treatment (n 5 64). Of these, 36 (55%) and 38
(59%) received the assigned treatment, respectively.
Analyses were on an ITT basis. The median interval
between randomization and auto-BMT was 64 days.
There were no significant differences in patient charac-
teristics between the 2 groups.
Rohatiner et al. [15] presented the results of a 2
sequential cohorts study comparing the outcomes of
144 adult (15-49 years) patients with AML enrolled in
the BXIII protocol (Italy, England) assigned to receive
an unpurged auto-BMT versus a comparison group of
patients who received traditional chemotherapy. Pa-
tients with APL were excluded. Eleven patients with
preceding MDS, which progressed to AML, were
included in the auto-BMT group, as were 43 other pa-
tients with varying degrees of MDS concurrent with
the diagnosis of AML. Of the 144 patients in the
auto-BMT group, 106 achieved CR1 and, of these,
61 proceeded to the assigned transplantation. Forty-
five patients did not receive the auto-BMT for the fol-
lowing reasons: early recurrence (n 5 17), medically
unfit (n 5 12), patient refusal (n 5 8), elective allo-
BMT (n 5 7), and insufficient cells (n 5 1). Patients
in the comparison group were from the same 3 insti-
tutions as those in the auto-BMT group and received
the identical remission induction and consolidation
therapy, but without the high-dose therapy and
auto-BMT. Analyses were on an ITT basis. With
the exception of the presence of MDS in the auto-
BMT group, patient characteristics were similar in
the 2 sequential cohorts.
Treatment schema III: induction, then ICC versus auto-SCT.
Cassileth et al. [16] reported the results of an inter-
group (EasternCooperativeOncologyGroup [ECOG],
Southwest Oncology Group [SWOG], Cancer and
Leukemia Group B [CALGB]) prospective study com-paring the outcomes of chemotherapy, auto-BMT, and
allo-BMT in 808 adult (16-55 years) patients with un-
treated AML.Of the 808 patients enrolled in the study,
36 were ineligible and 32 could not be evaluated (CR
not documented [n5 19]; missing follow-up data [n5
7]; withdrew before completing therapy [n 5 5]; CNS
leukemia detected [n5 1]), leaving 740 (92%) patients
eligible for induction therapy. Of these, 518 (70%)
achieved CR1; however, 172 patients were removed
from the study prior to randomization or assignment
to postremission therapy, leaving 346 patients in the
ITT analysis. The primary reasons for removal in-
cluded patient refusal to continue, persistent medical
problems after induction, and relapse before randomi-
zation. Patients with HLA-matched or single-antigen-
mismatched family donors (n5 113) were biologically
assigned to receive allo-BMT. The remaining 233 pa-
tients were randomized between auto-BMT (n5 116)
and high-dose cytarabine-based chemotherapy (n 5
117). Randomization to the 2 arms was stratified
according to age (#45 versus .45 years), FAB type
(M1, M2, M3, M4 versus M0, M5, M6, M7), the
number of induction courses to achieve CR (1 versus
2), and cytogenetics (favorable 5 t[8;21], t[15;17], or
inv[16]; normal or having a single abnormality;
unfavorable55q2, 25, 7q2, abnormal chromosome 9
or 11, or 3 or more clonal abnormalities). There were
no statistically significant differences among the treat-
ment groups on any of these patient characteristics.
Median times from CR1 to postremission therapy
were 14.1, 14.6, and 12.4 weeks for allo-BMT,
auto-BMT, and chemotherapy, respectively. Actual re-
ceipt of intended therapy was as follows: allo-BMT,
n 5 90 (80%); auto-BMT, n 5 63 (54%); chemother-
apy, n 5 106 (91%).
Bassan et al. [17] presented the results of 153 adult
(15-60 years) patients with AML enrolled in the BXIII
Protocol, a postremission, nonrandomized, collabora-
tive study between the Bergamo/Vicenza Hospitals in
Italy and St. Bartholomew Hospital in England.
Patients with APL were excluded. There were 147
patients with de novo AML and 6 with secondary
AML. Of the 153 patients, 108 (70%) achieved CR1;
however, 1 patient refused further treatment, leaving
107 in CR1. Seventy-four patients\50 years started
first consolidation, of whom 41 had an auto-BMT
(55%). Seven patients with HLA-matched sibling
donors underwent allo-BMT and were excluded from
the analysis. Additional reasons patients did not receive
an auto-BMT included relapse (n 5 8), infection
(n 5 15), thrombocytopenia (n 5 1), patient refusal
(n 5 1), or inadequate bone marrow harvest (n 5 1).
Of the 33 patients .50 years, 2 died of infection, 2
relapsed, and 10 had complications or very poor perfor-
mance status, leaving 19 patients (plus 5 patients
from the\50 age group) to receive the planned chemo-
therapy. Both groups were similar with regard to sex,
144 D. M. Oliansky et al.FAB, blast cell count, cytogenetics, and incidence of
hepatosplenomegaly.
Allogeneic SCT versus Chemotherapy ±
Autologous SCT in CR1
Four of the studies already described in the previ-
ous section included allo-BMT versus chemotherapy
(6 auto-BMT) comparisons [9-11,16]. Because allo-
BMT involves biologic assignment, as opposed to ran-
domization, comparisons of allo-BMT versus auto/
chemo are graded as cohort studies and rated as level
‘‘2’’ evidence. Therefore, outcome results that relate
to allo-BMT from these studies are presented in Table
4 under the section ‘‘Allo-BMT versus Chemotherapy
6 Auto-BMT in CR1.’’ Following are the descriptions
of several additional cohort studies of allo-BMT versus
chemotherapy (6 auto-BMT) inCR1, the outcomes of
which are presented in the same section of Table 4.
Myeloablative conditioning for allo-SCT. Yanada et al.
[18] presented the results of a meta-analyses of 5 stud-
ies comparing the efficacy of allo-SCT versus chemo-
therapy and/or auto-SCT in adult (10-55 years)
patients with AML in CR1. Study requirements for
potential inclusion in the meta-analysis included: pub-
lished in English between 1995 and 2003, only patients
with AML, offered allo-HSCT to all patients in CR1
with an HLA-matched sibling and chemotherapy or
auto-SCT to all others, used ITT analyses to compare
patients on the basis of donor availability, and assessed
outcomes in terms of OS. Studies were excluded if they
dealt exclusively with children, analyzed outcomes by
actual treatment given, did not offer allo-SCT to all
patients with a donor, if other articles from the same
trials were eligible, or the hazard ratio (HR) and
95% CI for OS could not be assessed. A total of
3100 patients received allo-SCT (n5 1151) or alterna-
tive treatments (n 5 1949) in the 5 studies. HRs were
used to assess the survival advantage of allo-SCT ver-
sus alternative treatments. HRs and 95% CIs were ab-
stracted from each study, and a general variance-based
method was used to estimate the summary HR and the
95% CI for OS. Outcomes were analyzed by cytoge-
netic risk. Figure 2 presents a Forrest plot of the
HRs and 95% CIs for OS from the 5 studies included
in the meta-analysis.
Cornelissen et al. [19] reported the results of
a retrospective analysis of the Dutch-Belgium
Hemato-Oncology Cooperative Group and the Swiss
Group for Clinical Cancer Research (HOVON-
SAKK) collaborative study of 925 adult (15-55 years)
patients with AML in 3 consecutive studies (AML4,
AML29, and AML42) comparing donor (n5 326) ver-
sus no donor outcomes (n 5 599). Patients with APL
were excluded. Patients were assigned to the no donor
group as a result of absence of siblings, HLA-incom-
patibility, or ineligibility of a potential donor. The 2
groups were comparable with respect to age, FABtype, WBC count at diagnosis, number of cycles to
CR1, and cytogenetics. Of the 326 patients with an
HLA-matched sibling donor, 268 (82%) underwent
an allo-HSCT, 17% received a third cycle of chemo-
therapy, and 1% an autograft. In the no donor group,
65% underwent chemotherapy consolidation, 28% re-
ceived an auto-SCT, and 8% received a mismatched
related or unrelated allo-SCT. Analyses were on an
ITT basis. Figure 3 compares the actuarial rates of
DFS between the donor and no donor groups.
Burnett et al. [20] presented a donor versus no
donor analysis of 1063 HLA-typed adult (\55 years)
Figure 2. Forrest plot of the HRs and 95% CIs for OS. Study iden-
tifications are provided below. FEMandREMdenote summaryHRs
by the fixed-effect and random-effect models. The varying sizes of
the filled diamonds represent the weight for the fixed-effect model
in the meta-analysis. A hazard ratio greater than unity means that al-
logeneic transplantation is superior to nonallogeneic transplanta-
tion. Study IDs: 1-1: Reiffers et al. [10]; 2-1: Keating et al., Br J
Haematol. 1998;102:1344-1353; 3-1 to 3-6: Slovak et al. [116]; 4-1
to 4-5: Burnett et al. [20]; 5-1 to 5-4: Suciu et al. [30]. (Reprinted
with permission; [18].)
Figure 3. Actuarial rates of DFS of patients with AML in first
complete remission according to donor availability. (Reprinted
with permission; [19].)
tion
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif) Outcome Defined
(Interval)
% OS
(Signif)
(Overall EFS)
RR§ 5 0.85
(CI 0.75-.97)
Auto versus Chemo
(P signif, but not
stated)
Not stated (Not stated)
RR 5.94
(CI .81-1.09)
(P not signif)
(4-yr DFS)
48 ± 5
30 ± 4
(P 5 .05)
Time from CR1
to first relapse or
death in CR
(4-yr OS)
56 ± 5
46 ± 5
(P 5 .43)
(3-yr DFS)
51 ± 17
58 ± 16
(P not signif)
Time from CR1 to
relapse, death, or
last visit
(3-yr OS)
56 ± 16
55 ± 16
(P not signif)
(4-yr DFS)
44 ± 5.5
40 ± 5.5
(P 5 .41)
Time from CR1 to
relapse or death
(4-yr OS)
50 ± 6
54 ± 6
(P 5 .72)
(5-yr LFS)
69.6
41.9
(P 5 .008)
Not stated Not stated
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Reference [No.]
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients by
Study Group
Upper
Limit
(median)
Age at
Diagnosis
(Interval)
% Tx-
Related
Mortality
Median
Follow-up
AUTOLOGOUS SCT VERSUS CHEMOTHERAPY IN CR1‡
Levi et al., 2004
[7]
111 Meta-analysis
(6 RCT studies)
1984-1996
Recruited n 5 4410
Achieved CR1 n5 3220
Randomized n 5 1044
(ITT)
Auto 524
Chemo/no further TX
520
\60 yrs
(Not
stated)
Not
stated
Not stated
Treatment Schema I: Induction 1 ICC, then Auto-SCT versus Additional ICC
Zittoun et al., 1995
[9]
(included in Levi et
al., meta-analysis)
11 EORTC and GIMEMA
1986-1993
Multicenter (59)
Recruited n 5 990
Evaluable n 5 941
Achieved CR1 n 5 623
Randomized n 5 254
(ITT)
Auto 128
Chemo 126
#59 yrs
(33 yrs)
Not
stated
3.3 yrs
Reiffers et al., 1996
[10]
(included in Levi et
al. and Yanada et al.,
meta-analyses)
11 BGMT 87 trial
1987-1990
Multicenter (4)
Enrolled n 5 204
Achieved CR1 n 5 162
Randomized n 5 77
(ITT)
Auto 39
Chemo 38
#55 yrs
(39.8 yrs)
(Not
stated)
6
0
Minimum
Follow-up
40 months
Harousseau et al.,
1997
[11]
(included in Levi et
al., meta-analysis)
12 GOELAM
1987-1994
Multicenter (16)
Recruited n 5 535
Evaluable n 5 504
Achieved CR1 n 5 367
Randomized n 5 164
(ITT)
Auto 86
Chemo 78
#50 yrs
(36 yrs)
(Not
stated)
6.5
3
62 mos
Miggiano et al., 1996
[12]
21 Retrospective
Nonrandomized
1987-1994
Single center
Included n 5 89
Total 89
(Actual TX)
Auto 51
Chemo 38
\60 yrs
(mean age)
(36)
(44)
(Not
stated)
0
(Not
stated)
Mean
Follow-up
35 mos
Outcome Defined
(Interval)
% OS
(Signif)
Time from
randomization to
relapse or death
in CR1
(7-yr OS)
57
45
(P 5 .20)
Not stated (5-yr OS)
39 ± 6
56 ± 6
(P 5 .08)
Not stated (5-yr OS)
K-M curves only
(Auto versus Chemo,
P 5 .009)
Time from CR1
to 1st relapse or
death from any
cause
(4-yr OS)
43 ± 9
52 ± 9
(P 5 .05)
Time from CR1 to
relapse or death
in CR
(5-yr OS)
60
65
(P not signif)
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Reference [No.]
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients by
Study Group
Upper
Limit
(median)
Age at
Diagnosis
(Interval)
% Tx-
Related
Mortality
Median
Follow-up
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif)
Treatment Schema II: Induction 1 ICC, then Auto-SCT versus No Further Treatment
Burnett et al., 1998
[13]
(included in Levi et
al. meta-analysis)
12 UK MRC AML 10
1988-1995
Multicenter (163)
Recruited n 5 1966
Evaluable n 5 1857
Achieved CR1 n5 1509
Eligible for
Randomization
n 5 1001
Randomized n 5 381
(ITT)
Auto 190
Chemo only 191
\55 yrs
(Not
stated)
Not stated 4.8 yrs (7-yr DFS)
53
40
(P 5 .04)
Breems et al., 2004
[14]
12 HOVON & SAKK
1987-1995
Recruited n 5 646
Achieved CR1 n 5 425
Randomizable n 5 344
Randomized n 5 130
Randomized n 5 130
(ITT)
Auto 66
No further TX 64
(Chemo only)
\60 yrs
(Mean age
52 yrs)
Not stated 154 mos (5-yr DFS)
35 ± 6
44 ± 6
(P 5 .68)
Rohatiner et al., 2000
[15]
21 BXIII Protocol
1988-1994
Multicenter (3)
Recruited n 5 144
Achieved CR1 n 5 106
Pre-1988 Comparison
Group n 5 133
Total n 5 239 (ITT)
Auto 106
Chemo 133
\50 yrs
(38 yrs)
Not stated 5.5 yrs (5-yr RFS)
K-M curves only
(Auto versus Chemo,
P 5 .002)
Treatment Schema III: Induction, then ICC versus Auto-SCT
Cassileth et al., 1998
[16]
(included in Levi et
al., meta-analysis)
11 CALGB, ECOG,
SWOG
1990-1995
Intergroup,
multicenter study
Recruited n 5 808
Evaluable n 5 740
Achieved CR1 n5518
Randomized n5233
Randomized n 5 233
(ITT)
Auto 116
Chemo 117
# 55 yrs
(Not
stated)
(\100 d)
14
3
4 yrs (4-yr DFS)
35 ± 9
35 ± 9
(P 5 .77)
Bassan et al.,
1998
[17]
22 BXIII Protocol
Non-randomized
1987-1993
2 centers
Enrolled n 5 153
Achieved CR1 n 5108
Total n 5 65
Auto BMT 41
Chemo 24
#60 yrs
(37)
(55)
(Not stated)
7
8
Minimum
3.3 yrs
(5-yr RFS)
53
54
(P not signif)
Outcome Defined
(Interval)
% OS
(Signif)
Not stated (Not stated)
HR¶ 51.17
(CI 1.06 - 1.30)
(P 5 .003, Allo versus
alternative)
Time from
consolidation to
relapse or death
(4-yr OS)
54 ± 3
46 ± 2
(P 5 .09)
Time from CR1 to
relapse or death
(4-yr OS)
53 ± 5.5
53 ± 4.5
(P 5 .74)
Time from CR1 to
relapse, death, or
last visit
(3-yr OS)
65 ± 16
50 ± 13
(P not signif)
Time from CR1 to
relapse or death
in CR
(7-yr OS)
56
50
(P 5 .10)
Not stated (5-yr OS)
48 (CI 43-53)
42 (CI 33-51)
(P 5 .28)
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Reference [No.]
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients by
Study Group
Upper
Limit
(median)
Age at
Diagnosis
(Interval)
% Tx-
Related
Mortality
Median
Follow-up
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif)
ALLOGENEIC SCT VERSUS CHEMOTHERAPY ± AUTOLOGOUS SCT IN CR1
Myeloablative Conditioning for Allogeneic SCT
Yanada et al.
2005
[18]
11 Meta-analysis (5 allo-
SCT studies)
Published 1995-2003
Accrual 1986-1999
Total n 5 3100
Allo-SCT 1151
Alternative 1949
(Auto or chemo)
#55 yrs
(Not
stated)
Not stated Not stated Not stated
Cornelissen et al. 2007
[19]
211 HOVON-SAKK
AML4, AML29, and
AML42 trials
1987-2004
Recruited n 5 2287
Evaluable n 5 925
Total n 5 925 (ITT)
Donor 326
No Donor 599
(Auto or chemo)
#55 yrs
(39 yrs)
(4-yr)
21
4
63 mos (4-yr DFS)
48 ± 3
37 ± 2
(P\.001)
Harousseau
et al., 1997
[11]
211 GOELAM
1987-1994
Multicenter (16)
Recruited n 5 535
Evaluable n 5 504
Achieved CR1 n 5 367
Total n 5 222 (ITT)
Donor 88
No Donor 134
(Chemo)
#40 yrs
(Not
stated)
(Not stated)
22
3
62 mos (4-yr DFS)
44 ± 5.5
38 ± 4
(P 5 .62)
Reiffers et al., 1996
[10]
211 BGMT 87
1987-1990
Multicenter (4)
Eligible n 5 204
Achieved CR1 n 5 162
Total n 5 96 (ITT)
Donor 36
No Donor 60
(Auto or chemo)
#45 yrs
(32 yrs)
(34 yrs)
(Not stated)
12
3
Minimum
Follow-up
40 months
(3-yr DFS)
66 ± 16
56 ± 13
(P\.05)
Burnett et al., 2002
[20]
(Included in Yanada
et al. meta-
analysis)
21 UK MRC AML 10
1988-1995
Multicenter (163)
Recruited n 5 1966
Evaluable n5 1857
Achieved CR1 n51509
Total n 5 1287 (ITT)
Donor 419
No Donor 868
(including 200 auto)
\55 yrs
(Not
stated)
Not stated 80 mos (7-yr DFS)
50
42
(P 5 .01)
Gale et al., 1996
[21]
21 Retrospective
IBMTR (transplant);
GAMLCG (chemo)
1985-1993
Multicenter (401)
Included n 5 1097
Total n 5 1097
(Actual TX)
Allo 901
Chemo 196
#50 yrs
(30)
(36)
(5-yr)
43 (37-49)
7 (3-11)
Not stated (5-yr LFS)
46 (CI 42-50)
35 (CI 28-41)
(P 5 .01)
Outcome Defined
(Interval)
% OS
(Signif)
)
Time from CR1
to 1st relapse or
death in CR
(4-yr OS)
59 ± 4
46 ± 5
(P not signif)
Time from CR1
to 1st relapse or
death from any
cause
(4-yr OS)
46 ± 10
52 ± 9
(Chemo versus Allo,
P 5 .04)
o
Time from CR1
relapse or death
(4-yr OS)
42 ± 14
43 ± 18
19 ± 17
(Allo versus Maint.
Chemo
P 5 .047)
Not stated (5-yr OS)
45 ± 24
53 ± 16
(P not signif)
Time from CR1 to
relapse or death
Not stated
Time from CR1 to
relapse, death, or
last contact
(7-yr OS)
41 ± 22
46 ± 19
(P 5 .10)
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Reference [No.]
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients by
Study Group
Upper
Limit
(median)
Age at
Diagnosis
(Interval)
% Tx-
Related
Mortality
Median
Follow-up
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif)
Zittoun et al.,
1995
[9]
21 EORTC & GIMEMA
1986-1993
Multicenter (59)
Recruited n 5 990
Achieved CR1 n 5 623
Total n 5 294 (ITT)
Allo 168
Chemo 126
#59 yrs
(33 yrs)
Not stated 3.3 yrs (4-yr DFS)
55 ± 4
30 ± 4
(Allo versus chemo, P\.05
Cassileth et al., 1998
[16]
21 CALGB, ECOG,
SWOG
1990-1995
Intergroup,
multicenter study
Eligible n 5 808
Achieved CR1 n 5 518
Total n 5 230 (ITT)
Allo 113
Chemo 117
#55 yrs
(Not
stated)
(\100 d)
21
3
4 yrs (4-yr DFS)
43 ± 10
35 ± 9
(P not signif)
Cassileth et al.,
1992
[22]
21 ECOG
1984-1988
Recruited n 5 534
Evaluable n 5 449
Achieved CR1 n 5 305
Allo, n 5 54, compared
with subset of chemo
pts.\41 yr, n 5 50)
Total n 5 104 (ITT)
Allo 54
Consolidation
chemo 29
Maintenance
chemo 21
\ 41 yrs
(26)
(31)
(34)
(Not stated)
36
21
0
4 yrs (4-yr EFS)
42 ± 13
30 ± 17
14 ± 15
(Allo versus Maint. Chem
P 5 .01)
Schiller et al.,
1992
[23]
21 ALP 3 and 4
1982-1990
2 centers
Recruited n 5 103
Achieved CR1 n 5 82
Total n 5 82
(Actual TX)
Allo 28
Chemo 54
#45 yrs
(33 yrs)
(4-yr)
32
6
4 yrs (5-yr DFS)
48 ± 21
38 ± 14
(P not signif)
Willemze et al.,
1991
[24]
21 Retrospective
1983-1989
Single center
Included n 5 107
Total n 5 78
(Actual TX)
Allo 44
Chemo 34
#62 yrs
(41 yrs)
(8-yr)
17
6
18 mos (3-yr DFS)
30 (CI 19-45)
25 (CI not stated)
(P 5 .45)
Archimbaud et al,
1994
[25]
21 LYLAM-85
1985-1990
Single center
Recruited n 5 172
Subset\40 yr of age
n 5 78
Achieved CR1 n 5 58
Total n 5 58
(ITT)
Donor 27
No Donor 31
(Chemo)
\40 yrs
(31 yrs)
(Not
stated)
22
13
63 mos (7-yr LFS)
41 ± 22
27 ± 16
(P not signif)
erval)
Tx-
lated
rtality
Median
Follow-up
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif) Outcome Defined
(Interval)
% OS
(Signif)
Not
tated)
12
stated
31 mos (4-yr LFS)
54
30
(P 5 .01)
Time from DX to
relapse
(4-yr OS)
Data Not stated
(P 5 .04)
-yr)
56
7
60 mos
30 mos
(3-yr LFS)
26 (CI 20-32)
17 (12-23)
(P not signif)
Not stated Not stated
chemotherapy; BMT, bone marrow transplantation; SCT, stem cell transplantation; CR, complete
anization of Research and Treatment of Cancer; GIMEMA, Gruppo Italiano Malattie Ematologiche
gy Group; SWOG, Southwest Oncology Group; GOELAM, Groupe Ouest Est Leucemies Aigue¨s
ative Group; ALP, acute leukemia protocol; HOVON, Dutch Hemato-Oncology Working Party;
-treat; DFS, disease-free survival; EFS, event-free survival; RFS, relapse-free survival; Signif., signif-
galy; PS, performance status; RR, rate ratio; CI, 95% confidence interval.
motherapy.
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Reference [No.]
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients by
Study Group
Upper
Limit
(median)
Age at
Diagnosis
(Int
%
Re
Mo
REDUCED INTENSITY CONDITIONING (RIC) FOR ALLOGENEIC SCT
Mohty et al., 2005
[26]
22 Retrospective
1999-2003
Single center
Included n 5 95
Total n 5 95 (ITT)
Donor 35
No Donor 60
#65 yrs
(52 yrs)
(
s
Not
ALLOGENEIC SCT VERSUS CHEMOTHERAPY IN CR2
Gale et al.,
1996
[27]
21 Retrospective
MRC, ECOG, IBMTR
1980-1989
Multicenter (801)
Total n 5 501
Allo 257
Chemo 244
#50 yrs
(26 yrs)
(35 yrs)
(3
*Quality and strength of evidence definitions are listed in Table 1.
†AML indicates acute myelogenous (myeloid) leukemia; Allo, allogeneic; Auto, autologous; Chemo,
remission; DX, diagnosis; TX, treatment; MRC, Medical Research Council; EORTC, European Org
Maligne dell’Adulto; CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncolo
Myeloblastiques; IBMTR, International Bone Marrow Registry; GAMLCG, German AML Cooper
STT, short-term therapy; FAB, French, American, British morphology classification; ITT, intent-to
icance (probability); OS, overall survival; WBC ct, white blood cell count; Hepato., hepatosplenome
‡Auto versus allo-SCT outcomes are presented in Table 5.
§Relative Risk (RR) less than 1 indicates significant survival benefit for auto-SCT as compared to che
¶Hazard Ratio (HR) greater than 1 indicates allo-SCT is superior to nonallogeneic SCT.
Further Treatment
rses:
mg/
to
If donor available, Allo-SCT (34% of pts) using
Cy (60 mg/kg/day  2) 1 TBI (12 Gy)
Or
Bu (4 mg/kg/day  4) 1 Cy (60 mg/kg/day X 2)
If no donor, randomized to HiDAC (Ara-C 4
mg/m2/day  4 1 DNR 45 mg/m2/day  3)
Or
Auto-SCT (55% of pts) using Bu (4 mg/kg/day
X 4) 1 Cy (60 mg/kg/day  2)
es:
/m2/
If donor available and #45 years, Allo-SCT
using Bu (4 mg/kg/day  4) 1 Mel (140/m2/
day  1)
If no donor or . 45 years, randomized to 2
years maintenance using Ara-C (100 mg/m2/
day  5) 1 DNR (1 mg/kg i.v.  1)
administered at 1, 3, 6, 9, and 12 mos
Or
Auto-SCTusing Bu (4 mg/kg/day  4) 1 Mel
(140/m2/day  1)
If donor available and #40 years, Allo-SCT
using myeloablative regimen:
Bu (4 mg/kg/day  4) 1 Cy (50 mg/kg/day  4 or
60 mg/kg/day  2)
Or
Cy (60 mg/kg/day  2) 1 TBI (dose not stated)
If no donor or .40 years, randomized to:
second ICC using AMSA (150 mg/m2/day  5) 1
VP-16 (100 mg/m2/day  5)
Or
Auto-SCTusing Bu (4 mg/kg/day  4) 1 Cy
(50 mg/kg/day  4)
Auto-SCTusing Bu (4mg/kg/day X 4) 1 Cy
(50 mg/kg  4 days or 60 mg/kg/day  2 days)
Nonrandomized control group received
monthly maintenance chemotherapy (drug
and dosage not stated)
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SCT versus Chemo Study
[Strength of Evidence*] [Ref No.] Induction Intensive Consolidation
Induction 1 ICC, then Autologous SCT versus Additional ICC
Zittoun et al., 1995 [11] [9] DNR†(45 mg/m2/day  3) 1 Ara-C (200 mg/m2/
day  7); second course if partial or no CR
For patients who achieved CR after 1-2 cou
AMSA (120 mg/m2/day  3) 1 Ara-C (2000
m2/day  6 for first 75 pts, then decreased
1000 mg/m2/day  6 for subsequent pts)
Reiffers et al., 1996 [11] [10] Ara-C (100 mg/m2/day  10) 1 DNR (60 mg/m2/
day  3); second course if partial or no CR
For all pts who achieved CR after 1-2 cours
Ara-C (100 mg/m2/day  7) 1 DNR (60 mg
day  2)
Harousseau et al., 1997 [11] [11] Ara-C (200 mg/m2/day  7) 1 IDR (8 mg/m2/day
 5) or RBZ (200 mg/m2/day  4)
For pts in CR waiting for Allo-BMT:
AMSA (150 mg/m2/day  1) 1 Ara-C
(100 mg/m2/day  5)
For all other pts in CR:
HiDAC (6 g/m2/day  4) 1 IDR
(10 mg/m2/day  2)
Or
HiDAC (6000 mg/m2/day  4) 1 RBZ
(200 mg/m2/day  2)
Miggiano et al., 1996 [21] [12] (Exact dosage not provided)
DNR 1 Ara-C ± VP-16
Or
ICE (IDR 10 mg/m2 1 Ara-C 1 VP-16)
Or
IDR (10 mg/m2) ± Ara-C
For all pts who achieved CR after
1-2 courses: (Exact dosage not provided)
Ara-C 1 AMSA
Or
Ara-C (conventional dose) 1 MITO
Further Treatment
If donor available, pts received 1 course
MidAC: MITO (10 mg/m2/day  5) 1 Ara-C
(2000 mg/m2/day  3); followed by Allo-SCT
using Cy (120 mg/kg/day  2) 1 TBI (1200 or
1440 Gy)
No donor available, pts received 1 dose MidAC,
then randomized to:
No further treatment
Or
Auto-SCTusing Cy (120 mg/kg/day  2) 1 TBI
(1200 or 1440 Gy)
If donor available, pts received Allo-SCT
(regimen not stated)
No donor available, pts randomized to:
No further treatment
Or
Auto-SCTusing Bu (4 mg/kg/day  4) 1 Cy
(1550 mg/m2/day  4)
Auto-SCTusing Ara-C (2000 mg/m2/day  6) 1
TBI (400 cGy/day  3)
Nonrandomized, historical control group
received no further treatment
If donor available, pts received Allo-SCTusing
Bu (4 mg/kg/day  4) 1 Cy (50 mg/kg/day  4)
No donor available, pts randomized to:
HiDAC (6000 mg/m2/day  6)
Or
Auto-SCTusing Bu (4 mg/kg/day  4) 1 Cy
(50 mg/kg/day  4)
Pts . 50 years received 1 course HiDAC
(2000 mg/m2/day  6) ± Dox at the
physician’s discretion (dose not stated)
Pts 15-50 years received HiDAC (2000 mg/m2/
day  6)1 TBI (400 cGy/day  3)1 Auto-SCT
mide; TBI, total body irradiation; Bu, Busulfan, IDR,
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SCT versus Chemo Study
[Strength of Evidence*] [Ref No.] Induction Intensive Consolidation
Induction 1 ICC, then Autologous SCT versus No Further Treatment
Burnett et al., 1998 [12] [13] Pts randomized to:
DNR (50 mg/m2/day  3) 1 Ara-C (200 mg/m2/
day  10) 1 TG (200 mg/m2/day  10);
followed by DNR (50 mg/m2/day  3) 1
Ara-C (200 mg/m2/day  8) 1 TG
(200 mg/m2/day  8) whether in CR after
first course or not
Or
Ara-C (200 mg/m2/day  10) 1 DNR
(50 mg/m2/day  3) 1 VP-16 (100 mg/m2/
day  5); followed by Ara-C (200 mg/m2/day
 8) 1 DNR (50 mg/m2/day  3) 1 VP-16 (100
mg/m2/day  5) whether in CR after first
course or not
All pts in CR received MACE [AMSA (100 mg/
m2/day  5)1 Ara-C (200 mg/m2/day  5)1 VP-
16 (100 mg/m2/day  5)]
Breems et al., 2004 [12] [14] DNR (45 mg/m2/day  3) 1 Ara-C (200 mg/m2/
day  7); followed by AMSA (120 mg/m2/day 
3) 1 Ara-C (2000 mg/m2/day  6) whether in
CR after first course or not
All pts who achieved CR received:
MITO (10 mg/m2/d  5) 1 VP-16
(100 mg/m2/day  5)
Rohatiner et al., 2000 [21] [15] Dox (25 mg/m2 i.v.  3) 1 Ara-C (100 mg/m2 i.v.
 7) 1 6-TG (100 mg/m2 po  7); second
course if partial or no CR
All pts who achieved CR received 2 additional
cycles of induction regimen
Induction, then ICC versus Autologous SCT
Cassileth et al., 1998 [11] [16] IDR (12 mg/m2/day  3) 1 Ara-C (25 mg/m2
followed by 100 mg/m2/day  7)
All pts who achieved CR received another
course of induction therapy at the same daily
doses, but with only 2 days of IDR and 5 days
of Ara-C
Bassan et al., 1998 [22] [17] Dox (25 mg/m2/day  3) 1 Ara-C (100 mg/m2/
day  7) 1 6-TG (200 mg/m2/day  7)
All pts in CR received 2 additional induction
therapy courses
ICC, intensive consolidation chemotherapy; DNR, daunorubicin; AMSA, Amsacrine; Ara-C, Cytarabine; HiDAC, high-dose Ara-C; Cy, cyclophospha
Idarubicin; Mel, Melphalan, TG, Thioguanine; VP-16, etoposide; MITO, Mitozantrone; RBZ, Rubidazone; Dox, Doxorubicin.
*Quality and strength of evidence definitions are listed in Table 1.
152 D. M. Oliansky et al.patients in the UK MRC AML-10 trial. Of these, 419
had a matched sibling donor and 644 had no match.
An additional 224 patients had no siblings and were
included in the no-donor group. Of the 419 patients
with a donor, 39% did not receive an allo-transplant.
Of the 868 patients with no donor, 661 received che-
motherapy and 207 received a transplant (auto-BMT,
n 5 200). Analyses were on an ITT basis and were
adjusted for cytogenetic risk group.
Gale et al. [21] reported the outcomes of a retro-
spective study of 1097 adults (16-50 years) with
AML. Patients who received an allo-BMT (n 5 901)
and were reported in the International Bone Marrow
Transplant Registry (IBMTR) were compared to 196
patients treated with chemotherapy in the German
AML Cooperative Group (GAMLCG) AML86 trial.
The cohorts differed significantly by sex, age, WBC
count at diagnosis, and FAB types, which were
adjusted for in the multivariate analysis of outcomes.
Figure 4 compares the adjusted probability of LFS
between the allo-BMT and chemotherapy groups.
Cassileth et al. [22] compared the outcomes of allo-
BMT versus chemotherapy in 534 adult (15-65 years)
patients with AML enrolled in an ECOG study. Four-
teen patients were cancelled and 39 deemed ineligible
(inadequate pathology submission, n 5 13; age .65
years, n 5 2; other eligibility violations, n 5 6; and
erroneous diagnosis, n 5 18). Another 32 patients
were excluded from analysis because of major protocol
violations (n 5 19) or no follow-up documentation
(n 5 13). Of the 449 evaluable patients, 305 (68%)
achieved CR1. A subset of 104 patients \41 years
was assigned to allo-BMT (n5 54) if anHLA-compat-
ible sibling donor was available, or randomly assigned
to consolidation chemotherapy (n 5 29) or mainte-
nance chemotherapy (n 5 21). Forty-five (83%) of
the patients assigned an allo-BMT underwent the
treatment. Analyses were on an ITT basis. Except for
Figure 4. Adjusted probability of LFS of persons 16-50 years old
with AML in first remission in the IBMTR and GAMLCG data-
bases. Numbers in parentheses indicate numbers of persons at risk
at different intervals. (Reprinted with permission; [21].)age, there were no significant differences among the
groups in patient or leukemic characteristics (sex, per-
formance status, degree of weight loss, marrow cellu-
larity, splenic involvement, FAB types, cytogenetics,
WBC count at presentation, number of circulating
blasts, percentage of marrow blasts, number of induc-
tion cycles needed to achieve CR1, and time to CR1).
Schiller et al. [23] reported the outcomes of 103
adult (16-45 years) patients with AML treated accord-
ing to the Acute Leukemia Protocol (ALP) 3 and 4
regimens comparing allo-BMT versus chemotherapy.
Eighty-two (80%) of the patients achieved CR1.
Of these, 28 patients were assigned to undergo allo-
BMTandwere comparedwith 54 age-matchedpatients
assigned to consolidation chemotherapy. The median
interval from remission to allo-BMT was 44 days.
Patient characteristics of the 2 groups were similar for
age, sex, WBC count at diagnosis, FAB type, number
of cycles needed to achieve CR1, and cytogenetics.
Willemze et al. [24] presented the results of a single
center, retrospective study of 107 adult (15-65 years)
AML patients, comparing allo-BMT, auto-BMT,
and chemotherapy postremission therapies. One pa-
tient died during the first consolidation course and
was excluded from the analysis. Thirty-four patients
received ICC, 28 were allocated to auto-BMT, and
44 to allo-BMT. There were no significant differences
among the 3 groups by age, sex, FAB type, or mean
interval (days) to reach CR1.
Archimbaud et al. [25] presented the results of 78
adult (17-39 years) AML patients treated on the
LYLAM-85 protocol comparing allo-BMT versus
chemotherapy at a single center in France, of whom
58 (74%) achieved a CR1. Twenty-seven of these
patients had an HLA-identical sibling donor and
were assigned to allo-BMT (donor arm), and 20 (74%)
actually underwent the procedure. The 31 patients
without a matched sibling donor were assigned to the
chemotherapy (no donor) arm, 24 (77%) of whom
received the scheduled 3 courses of chemotherapy.
Analyses were on an ITTbasis. The 2 groupswere sim-
ilar with regard to age, sex, WBC count at diagnosis,
FAB, percent blasts, platelet count, number of cycles
to CR1, days to CR1, and cytogenetics. There were
also no differences between the groups for the presence
of hemorrhage, organomegaly, or fever at diagnosis.
Reduced intensity conditioning (RIC) for allo-SCT. Mohty
et al. [26] presented the results of 95 adult (26-65 years)
patients withAMLenrolled at a single center inFrance.
All 95 patients were considered candidates for RIC
allo-BMT because of their high-risk leukemic or clini-
cal characteristics. Patients with an HLA-identical
sibling donor were assigned to the donor group (n 5
35, 37%), whereas the remaining 60 patients without
a donor were assigned to the no donor group and
treated according to ‘‘standard institutional proce-
dures.’’ In the donor group, 25 (71%) patients actually
The Role of Cytotoxic Therapy with HSCT 153underwent allo-BMT.The reasons for not receiving an
allo-BMT included patient refusal (n 5 60), early
relapse (n5 2), and psychiatric disorders (n5 2). Out-
come analyses were on an ITT basis. There were no
significant differences between the 2 groups by age,
sex, type of AML, FAB, cytogenetic risk group, or
number of induction cycles to achieve CR1.
Allogeneic SCT versus Chemotherapy in Second
Complete Remission (CR2)
Gale et al. [27] presented the outcomes of 501
adult (\50 years) patients with AML in CR2 who un-
derwent chemotherapy (n5 244) in MRC, ECOG, or
single center trials, or HLA-matched sibling donor
allo-HSCT (n 5 257) at IBMTR centers. Allo-HSCT
patients were younger, had briefer first remissions,
and more had FABM2 subtype than chemotherapy pa-
tients.The 2 groupswere similarwith respect to sex and
WBC count at diagnosis. Outcomes were adjusted for
time-to-treatment, age, and duration of CR1.
AUTOLOGOUS VERSUS ALLOGENEIC HSCT
Three studies previously described in the HSCT
versus Chemotherapy section [9,16,24] also included
comparisons between allo-HSCT versus auto-HSCT
outcomes, which are presented in Table 6. This sec-
tion provides descriptions of additional studies focus-
ing exclusively on the comparison of allo-HSCT
versus auto-SCT, which are also presented in Table 6.
The highest quality studies are presented first; studies
of equal quality are presented in descending order by
sample size.
Ringden et al. [28] presented the results of a retro-
spective study of 4536 patients (75% .17 years) with
AML in CR1 reported to the European Group for
Blood and Marrow Transplantation (EBMT) registry,
comparing auto-BMT (n53796), HLA-identical sib-
ling allo-BMT (n5 696), and twins allo-BMT (n5 44).
Auto-BMT patients tended to be older, the year of
their transplant was later, and the interval fromdiagno-
sis to BMT was longer than for the other 2 groups.
Lazarus et al. [29] presented the retrospective anal-
ysis of 1144 AML patients (#58 years; 81%.10 years)
transplanted in CR1 or CR2 and reported to the Cen-
ter for International Blood and Marrow Transplant
Research (CIBMTR), comparing the outcomes of
auto-BMT (n 5 668 patients) to unrelated donor
(URD) allo-BMT (n 5 476 patients). Analysis of pa-
tient characteristics between the 2 groups indicated
that a higher proportion of auto-BMT patients were
\ 10 years of age, and allo-BMT patients were more
likely to be male, have a lower performance score, un-
favorable cytogenetics, and require more time to
achieve CR1. Median times from remission to trans-
plantation were 102 and 104 days for auto-BMT and
allo-BMT patients, respectively. Multivariate analysesconsidered the impact of disease status, FAB, cytoge-
netic risk group, and cytomegalovirus (CMV) status
on outcomes.
Suciu et al. [30] compared the outcomes of allo-
BMT versus auto-HSCT in 1198 adult (15-46 yrs) pa-
tients with AML enrolled in the EORTC/GIMEMA
AML-10 protocol. Patients with APL were excluded.
Of the 1198 patients, 62 could not be evaluated because
of a lack of clinical documentation. Of the remaining
1136 patients, 822 (72.4%) achieved CR1. Fifty pa-
tients were excluded from further protocol treatment
because of toxicity (n 5 27), poor documentation
(n 5 15), or other reasons (n 5 8). Of the 772 patients
who received consolidation, 38 were not HLA-typed
because of patient refusal (n 5 9), early death/toxicity
(n 5 20), logistic reasons (n 5 5), or other reasons
(n 5 4). Of the remaining patients, 293 had an HLA-
matched sibling donor (donor group) and were as-
signed to receive an allo-HSCT. The remaining 441
patients either had no siblings or noHLA-matched sib-
ling and were assigned to receive an unpurged auto-
PBSCT or BMT (no-donor group). Allo-HSCT was
actually performed in 202 of 293 (68.9%) donor group
patients, and 246 of 441 (55.8%) patients in the no-
donor group received the assigned auto-HSCT.Eleven
(2.5%) no-donor group patients received an allo-BMT
with stem cells from a matched unrelated or matched
related donor, while 7 (2.5%) patientswith a sibling do-
nor underwent auto-HSCT. Outcome analyses were
on an ITT basis. Patient characteristics, including
age,WBC count at diagnosis, FAB subtype, cytogenet-
ics, and theCR rate after the first induction coursewere
similar in the 2 groups. Figure 5 compares the DFS
between the donor and no donor groups.
Figure 5. DFS from CR according to donor availability. The esti-
mates of the 4-year DFS rates (6SE) for the donor group (dotted
line) and the no donor group (solid line) are given. The 4-year cumu-
lative incidence of relapse and of death in CR are given in italics at
the right of the graph. N indicates the number of patients; O, ob-
served number of events (relapse or death in first CR). P is deter-
mined by the log-rank test. (Reprinted with permission; [30].)
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and
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Number of Patients by
Study Group
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(Median)
Age at
Diagnosis
(Interval)
% TX-
Related
Mortality
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Ringden et al.,
2000
[28]
211 Retrospective
EBMT
1987-1999
Included n 5 6306
AML n 5 4536 (72%)
Total AML n 5 4536
HLA-ident. Sib allo 696
Twins allo 44
Auto 3796
#77 yrs
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5 ± 3
11 ± 1
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2006
[29]
211 Retrospective
CIBMTR
1989-1996
Multicenter (12)
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Reference No.
Quality
and
Strength
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Evidence* Patient Population†
Number of Patients by
Study Group
Upper
Limit
(Median)
Age at
Diagnosis
(Interval)
% TX-
Related
Mortality
Median
Follow-
up
(Inte
%D
%E
%R
%L
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Singhal et al.,
2003
[32]
21 Retrospective
1984-1999
2 centers
Included n 5 130 AML
Total n 5 130
(Actual TX)
PMRDTAllo 80
Auto 50
#73 yrs
(23 yrs)
(18 yrs)
(5-yr)
62
20
5 yrs (5-yr
1
2
(P 5
Mitus et al., 1995
[33]
21 Prospective
1987-1993
Multicenter (3)
Recruited n 5 94
Achieved CR1 n 5 84
Total n 5 84 (ITT)
Allo 31
Auto 53
#63 yrs
(33 yrs)
(42 yrs)
(Not stated)
32
9
Not
stated
(5-yr
56 (CI
45 (CI
(P 5
Willemze et al.,
1991
[24]
(Described in SCT
versus Chemo
section)
21 Retrospective
1983-1989
Single center
Included n 5 107
Total n 5 72
(Actual TX)
Allo 44
Auto 28
#62 yrs
(41 yrs)
(8-yr)
17
7
18 mos (3-yr
30 (CI
40 (CI
(P not
Cassileth et al.,
1993
[34]
21 Prospective
ECOG P-C 486
No dates provided
Multicenter
Recruited n 5 123
Evaluable n 5 111
Achieved CR1 n 5 83
Total n 5 58 (ITT)
Allo 19
Auto 39
#55 yrs
(32 yrs)
(36 yrs)
Not stated 31 mos (3-yr
42
54
(P not
Lo¨wenberg et al.,
1990
[35]
21 Retrospective HOVON
1984 -1987
Recruited n 5 117
Achieved CR1 n 5 90
Total n 5 53
(Actual Tx)
Allo 21
Auto 32
#60 yrs
(43 yrs)
(3-yr)
19
9
30 mos (3-yr
5
3
(P 5
Sierra et al., 1996
[36]
22 Prospective 1988-1993
Multicenter (10)
Recruited n 5 159
Achieved CR1 n 5 120
Total n 5 115 (ITT)
Allo 47
Auto 68
#50 yrs
(30 yrs)
(Not stated)
23
0
45 mos
37 mos
(4-yr
31
50
(P 5
*Quality and strength of evidence definitions are listed in Table 1.
†AML indicates acute myelogenous leukemia; Allo, allogeneic; Auto, autologous; Chemo, chemotherapy; BMT, bonemarrow transplantation; SCT, stem
treatment; URD, unrelated donor; MUD, matched-rnrelated donor; PMRDT, partially mismatched related donor transplant; PBSCT, peripheral blo
nization of Research and Treatment of Cancer; GIMEMA, Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto; CALGB, Cancer and Leukemi
Group; SWOG, Southwest Oncology Group; HOVON, Dutch Hemato-OncologyWorking Party; EBMT, European Group for Blood and Marrow T
Blood and Marrow Transplant Research; FAB, French, American, British morphology classification; ITT, intent-to-treat; DFS, disease-free survival; E
Signif., significance (probability); OS, overall survival; CI, 95% confidence interval.
156 D. M. Oliansky et al.Carella et al. [31] retrospectively analyzed159 adult
(#62 years) patients withAML inCR1who received an
allo-BMT (n5 104) or unpurged auto-BMT (n5 55)
at a single institution.Median times fromCR1 to trans-
plant were 150 and 144 days for allo-BMT and auto-
BMT patients, respectively. Patient characteristics for
the 2 groups, including sex, age, FAB, andWBC count
at diagnosis, were not compared.
Singhal et al. [32] presented a retrospective analysis
of adult (62%.15 years) patients with AML (n5 130,
44% of sample) beyond first CR, who received either
a partially mismatched related donor (PMRD) T cell-
depleted allo-BMT (n 5 80, 61.5%) or an unpurged
auto-BMT (n5 50, 38.5%). Patients inCR1, those un-
dergoing a second auto-BMT, and those with known
secondary leukemia were excluded. Age and sex distri-
bution were comparable between the 2 treatment
groups. PMRD allo-BMT patients were less likely
than auto-BMT patients to be in CR2 and more likely
to have active disease at the time of transplant.
Mitus et al. [33] reported the outcomes of 94 adult
(17-63 years) patients with AML enrolled in a prospec-
tive, multicenter study of induction therapy followed
by allo-BMT versus auto-BMT. Patients with ante-
cedent MDS, anemia, or other cytopenia were ex-
cluded. Of the 94 patients, 84 (89%) achieved CR1.
Patients\55 years with an HLA-compatible relative
were assigned to allo-BMT, and those without a donor
or who were age 55-65 years were assigned to auto-
BMT. Median times from CR1 to transplantation
were 236 and 190 days for auto-BMT and allo-
BMT, respectively. One patient in each group under-
went the opposite procedure. Outcome analyses were
on an ITT basis. There were no significant differences
between the 2 treatment groups by age, sex, FAB type,
WBC count at diagnosis, or cytogenetics.
Cassileth et al. [34] reported the results of 123
adult (15-55 years) patients with AML enrolled in
the ECOG P-C 486 trial. Twelve (10%) patients
were deemed ineligible for various reasons. Of the
111 eligible patients, 83 (75%) achieved CR1.
Twenty-five (30%) patients were off-study because
of infections or other disease (n 5 14), patient refusal
(n 5 9), or other reasons (n 5 2). The remaining
patients were assigned to allo-BMT (n 5 19) or
auto-BMT (n 5 39). Patient characteristics were not
significantly different between the 2 groups, except
that allo-BMT patients were significantly younger
than auto-BMT patients. The median time from
CR1 to auto-BMT was 8 weeks, and 35 of 39 patients
had an auto-BMT.Themedian time fromCR1 to allo-
BMTwas 9 weeks, and 17 of 19 patients underwent the
procedure. Analyses were on an ITT basis.
Lo¨wenberg et al. [35] presented the outcomes of
117 adult (15-60 years) patients with AML enrolled
in a Dutch Hemato-Oncology Working Party
(HOVON) study comparing allo-BMT, auto-BMT,and no further treatment. Ninety (77%) patients
achieved CR1 and, of these, 37 (41%) patients who
were eligible for auto-BMT received no further treat-
ment because of early relapse or death (n5 19), refusal
(n 5 6), insufficient graft (n 5 3), chronic infection
(n 5 3), or other reasons (n 5 6). Of the remaining
53 patients, 32 (36%) underwent an unpurged
auto-BMT and 21 (23%) underwent anHLA-matched
allo-BMT.Median times from CR1 to transplantation
were 3.8 and 3.0 months for auto-BMT and allo-
BMT, respectively. Auto-BMT patients were, on
average, 10 years older than allo-BMT patients. There
were no significant differences between the allo-BMT
and auto-BMT groups by sex, FAB type, or time to
CR1. Analyses were by actual treatment received.
Sierra et al. [36] presented the outcomes of adult
(79%$15 years) patients with AML enrolled in a pro-
spective, multicenter study comparing allo-BMT ver-
sus auto-BMT. Patients .51 years or those having
a history of MDS, previous treatment with cytotoxic
drugs or radiation, or a severe concomitant disease
were excluded. Of 159 patients, 120 (75%) achieved
CR1, and 115 were HLA-typed. Forty-seven (41%)
patients had an HLA-identical sibling donor and were
assigned to allo-BMT; 26 (55%) underwent the proce-
dure. Reasons for not receiving the assigned allo-BMT
included medical contraindications (n 5 13) and early
relapse (n 5 8). Sixty-eight patients (59%) were as-
signed to auto-BMTand, of these, 47 (69%) underwent
the procedure. Reasons for not receiving the assigned
auto-BMT included medical contraindications (n5 9),
early relapse (n 5 8), and patient refusal (n 5 3). Out-
come analyses were on an ITT basis. Median intervals
from CR1 to transplantation were 166 and 147 days
for auto-BMTand allo-BMT, respectively. There were
no significant differences between the 2 groups on age,
sex, WBC count at diagnosis, number of induction
courses to CR1, or time to CR1.
AUTOLOGOUS HSCT
This section provides descriptions of auto-HSCT
studies, the outcomes of which are presented in
Table 7. The highest quality studies are presented first;
studies of equal quality are presented in descending
order by sample size.
PBSCT Versus BMT
Reiffers et al. [37] presented the results of a retro-
spective, multicenter study comparing the use of
PBSC versus BM for auto-HSCT in 1393 patients
(#64 years) with AML and registered with the
EBMT. Patients received an auto-PBSCT (n 5 100),
purged auto-BMT (n 5 252), or unpurged auto-
BMT (n 5 1041). The significantly different patient
characteristics among the groups were age (greater in
PBSCT patients than purged auto-BMT patients)
l)
y
Median
Follow-up
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif) Outcome Defined
(Interval)
% OS
(Signif)
Not stated (2-yr LFS)
44 ± 6
49 ± 2
57 ± 3
(PB vs Purged
BM, P 5 .01;
PB vs Unpurged
BM, P 5 .22)
Onset not stated;
events were
relapse or death
(2-yr OS)
53 ± 6
56 ± 2
66 ± 3
(PB vs Purged
BM, P 5 .10;
PB vs Unpurged
BM, P 5 .85)
Not stated Not stated Not stated (4-yr OS)
77
63
(P 5 .15)
d) 67 mos (6-yr DFS)
58
33
(P 5 .009)
Time from SCT to
relapse
or death
(6-yr OS)
54
35
(P 5 .02)
57 mos (3-yr LFS)
56 (CI 47-64)
31 (CI 18-45)
(P not stated)
Onset not stated;
events were
relapse or death
(3-yr OS)
63 (CI 52-70)
40 (CI 25-55)
(P not stated)
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Reference No.
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients
by Study Group
Upper
Limit
(Median)
Age at
Diagnosis
(Interva
% Tx -
Related
Mortalit
PBSCT versus BMT
Reiffers et al.,
2000
[37]
21 Retrospective
EBMT Registry
1986-1994
Included n 5 1393
Total n 5 1393
PB Auto 100
Unpurged BM Auto 1041
Purged BM Auto 252
#64 yrs
(43 yrs)
(52 yrs)
(52 yrs)
(2-yr)
12 ± 5
11 ± 1
9 ± 2
Sirohi et al.,
2004
[38]
21 Retrospective,
matched
1996-2000
EBMT Registry
(n 5 114)
and Single center
(n 5 57)
Total n 5 171
PB Auto 114
Unpurged BM Auto 57
#66 yrs
(39 yrs)
(43 yrs)
(4-yr)
1
13
Vey et al.,
2004
[39]
21 Retrospective
1984-1998
Single center
Included n 5 101
Total n 5 101
PB Auto 43
BM Auto 58
#60 yrs
(46 yrs)
(Not state
0
8
Purged versus Unpurged
Miller et al.,
2001
[40]
21 Retrospective
ABMTR
1989-1993
Multicenter (41)
Included n 5 294
Subgroup CR1 w/in
6 mos n 5 209
Total CR1 w/in 6 mos
n 5 209
Purged BM auto 148
Unpurged BM auto 61
#60 yrs
(33 yrs)
(18 yrs)
(3-yr)
12
8
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif) Outcome Defined
(Interval)
% OS
(Signif)
(4-yr LFS)
63 ± 8
34 ± 7
(P 5 .05)
Onset not stated;
events were
relapse or death
Not stated
Not stated)
57
32
(P 5 .36)
Not stated Not stated
(3-yr LFS)
67
40
(P 5 .052)
Not stated (3-yr OS)
73
47
(Not stated)
(5-yr DFS)
8 (CI 63-73)
Time from CR1 to
relapse or
death in CR
(5-yr OS)
71
(8-yr EFS)
5 (CI 44-64)
Time from SCT to
relapse, 2ndary
AML or MDS, or
death
(8-yr OS)
62 (CI 50-72)
(3-yr LFS)
36 ± 5
Onset not stated;
events were
relapse or death
(3-yr OS)
47 ± 5
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Reference No.
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients
by Study Group
Upper
Limit
(Median)
Age at
Diagnosis
(Interval)
% Tx -
Related
Mortality
Median
Follow-up
Gorin et al.,
1990
[41]
21 Retrospective EBMT
Registry 1982-1987
Multicenter (34)
Included n 5 263
Subgroup SR, CR1,
TBI n 5 107
Total CR1, SR, TBI
n 5 107
Purged BM auto 30
Unpurged BM auto 77
#47 yrs
(30 yrs)
Not stated 28 mos
Chao et al.,
1993
[42]
21 Retrospective
1987-1992
Single Center
Included n 5 50
Total n 5 50
Purged BM auto 30
Unpurged BM auto 20
#60 yrs
(40 yrs)
(Not
stated)
14
overall
31 mos (
Tandem versus Single
McMillan et al.,
1990
[43]
2- No dates stated
Multicenter
Rec’d first auto BMT
n 5 82
Eligible for second auto
n 5 54
Received second auto
n 5 26
Total n 5 51
Double auto 26
Single auto 25
#57 yrs
(40 yrs)
(Not stated)
6
overall
31 mos
Single Arm Cohort Studies—Purging status not stated
Kim et al.,
2004
[44]
211 Retrospective
1993—not stated
Single center
Included n 5 174
Total CR1 n 5 174 \65 yrs
(34 yrs)
(Not
stated)
4
51 mos
6
Molee et al.,
2004
[45]
211 Retrospective
1986-2001
Single center
Transplanted n 5 145
Transplanted in CR1
n 5 117
Total CR1 n 5 117 #65 yrs
(43 yrs)
(1-yr)
6
53 mos
5
Gorin et al.,
2000
[46]
21 Retrospective
1984-1998
EBMT Registry
Included n 5 193
CR1 only n 5 147
Total CR1
n 5 147
#69 yrs
(63 yrs)
(3-yr)
15 ± 4
14 mos
rval)
FS/
FS/
FS/
FS
nif) Outcome Defined
(Interval)
% OS
(Signif)
LFS)
± 5
Onset not stated;
events were
relapse
or death
(5-yr OS)
56 ± 5
tated,
S)
12
Time from BMT to
relapse
or TRM
(Not stated, OS)
72 ± 12
DFS)
± 7
Time from CR1 to
relapse
or death
(5-yr OS)
61 ± 6
LFS)
27-51)
36-61)
.12)
Time from CR1 to
relapse
or death
(5-yr OS)
41 (CI 29-54)
53 (CI 39-66)
(P 5 .14)
DFS)
2
Time from BMT to
relapse
or death
(10-yr OS)
45
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Reference No.
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients
by Study Group
Upper
Limit
(Median)
Age at
Diagnosis
(Interval)
% Tx -
Related
Mortality
Median
Follow-up
(Inte
% D
% E
% R
% L
(Sig
Single Arm Cohort Studies—Purged BMT
Gorin et al.,
1999
[47]
21 Retrospective
1983-1997
Single center
Mafosfamide Purge
AML pts. n 5 165
CR1 only n 5 123
Total CR1 n 5 123 #65 yrs
(37 yrs)
(5-yr)
18 ± 4
Not stated (5-yr
53
Linker et al.,
1998
[48]
21 Retrospective
1986-1993
2 Centers
4-HC Purge
Included n 5 165
CR1 only n 5 50
Total CR1 n 5 50 \ 60 yrs
(37 yrs)
(Not
stated)
4
6.8 yrs (Not s
DF
70 ±
Isnard et al.,
2001 [49]
2- Retrospective
1982-1994
Single center
Mafosfamide Purge
Included n 5 108
Achieved CR n 5 92
Rec’d transplant n 5 61
(89% purged auto
BMT; 11% allo)
Total CR1 n 5 61 #60 yrs
(39 yrs)
Not stated 41 mos (5-yr
55
Single Arm Cohort Studies—Unpurged BMT
Jourdan et al.,
2005
[50]
21 Prospective BGMT 95
Randomized
No dates stated
Multicenter
Enrolled n 5 437
Achieved CR1 n 5 351
Randomized to
HiDAC regimens
n 5 128
Total n 5 128 (ITT)
HiDAC 1 dose 65
HiDAC 2 dose 63
#60 yrs
(49 yrs)
(48 yrs)
(Not stated)
8
8
73 mos (5-yr
39 (CI
48 (CI
(P 5
Meloni et al.,
1996
[51]
21 Retrospective
1984-1994
Single center
CR2 patients
Total n 5 60
(78% adults)
Total CR2
n 5 60
#54 yrs
(28 yrs)
Not stated 60 mos (10-yr
4
rval)
x -
ted
ality
Median
Follow-up
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif) Outcome Defined
(Interval)
% OS
(Signif)
tated 37 mos (2-yr DFS)
49 (CI 37-62)
Time from
consolidation
chemo to
relapse or death
Not stated
ot
ed)
2
30 mos (5-yr DFS)
55 (CI 45-65)
Time from
start of
consolidation
chemo to
relapse
or death
Not stated
ot
ed)
1
18 mos (Not stated,
DFS)
61
Not stated (Not stated, OS)
62
BMT, bone marrow transplantation; SCT, stem cell transplantation; CR, complete
w Transplant Registry; BGMT, Bordeaux-Grenoble-Marseille-Toulouse; ITT, in-
robability); OS, overall survival; CI, 95% confidence interval.
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Reference No.
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients
by Study Group
Upper
Limit
(Median)
Age at
Diagnosis
(Inte
% T
Rela
Mort
Stein et al.,
1996
[52]
21 Prospective
1989-1993
Single center
In CR1 n 5 60
Rec’d Auto BMT
n 5 44
Total CR1 n 5 60 (ITT) #55 yrs
(39 yrs)
Not s
Single Arm Cohort Studies – Unpurged PBSCT
Linker et al.,
2000
[53]
21 Prospective
1993-1998
Multicenter (6)
Enrolled in CR1
n 5 128
Rec’d auto PBSCT
n 5 117
Total CR1 n 5 128 (ITT) \70 yrs
(39 yrs)
(N
stat
Pavlovsky et al.,
1998
[54]
21 Prospective 1991-1996
Single center
Eligible in CR1 n 5 56
(80% adults)
Rec’d auto-PBSCT
n 5 54
Total CR1 n 5 56 (ITT) #64 yrs
(32 yrs)
(N
stat
1
*Quality and strength of evidence definitions are listed in Table 1.
†AML indicates acute myelogenous (myeloid) leukemia; Allo, allogeneic; Auto, autologous; Chemo, chemotherapy;
remission; TX, treatment; PBSCT, peripheral blood stem cell transplant; ABMTR, Autologous Blood and Marro
tent-to-treat; DFS, Disease-free survival; EFS, event-free survival; RFS, relapse-free survival; Signif., significance (p
The Role of Cytotoxic Therapy with HSCT 161and FAB subtype (fewer patients with APL in the
PBSCT group than in either the purged or unpurged
BM groups). The interval between CR1 and HSCT
was longer for purged or unpurged BMT than for
PBSCT, and the proportion of patients receiving total
body irradiation (TBI) was higher in the BMT groups
than the PBSCT group.
Sirohi et al. [38] reported the results of a retrospec-
tive matched case-control study comparing auto-BMT
versus PBSCT in adult (16-66 years) patients with
AML. Fifty-seven patients from a single institution
who underwent an unpurged auto-BMTwerematched
on cytogenetics, FAB subtype, CR1 to HSCT interval,
and agewith 114 patients from theEBMTregistry who
underwent a PBSCT. Patients in the auto-BMT group
were significantly older than the PBSCT patients, and
WBC count at diagnosis was higher in the PBSCT pa-
tients than the auto-BMT group. Median times from
CR1 to HSCT were comparable at 121 days and 119
days in the BM and PBSC groups, respectively.
Vey et al. [39] retrospectively studied the outcomes
of 101 adult (16-60 years) patients with AML who un-
derwent an auto-SCT at a single center. Patients with
APL (n 5 4) were included. The stem cell source for
patients transplanted pre-1994 was BM (n5 58); those
treated after 1994 received PBSC (n5 43). HSCTwas
performed at amedian of 3.5months fromCR1. There
were no significant clinical or biologic differences
between the 2 treatment groups.
Purged versus Unpurged
Miller et al. [40] presented the results of 209patients
(#60 years) reported to the Autologous Blood and
Marrow Transplant Registry (ABMTR) who received
either a purged (n 5 148) or unpurged (n 5 61)
auto-BMT for AML in CR1. BM was purged with
4-hydroperoxycyclophosphamide (4-HC). Patients
receiving purged BM were significantly younger, had
lower performance scores, were less likely to receive
consolidation chemotherapy, and were transplanted
sooner afterCR1 than patients receiving unpurgedBM.
Gorin et al. [41] presented the results of 263 pa-
tients (86% adult) with AML from the EBMT registry
who underwent a purged or unpurged auto-BMT. Of
the 263 patients, 231 were classified as standard risk
(SR) and 32 were high risk (HR). A comparison of
purged (n 5 30) versus unpurged (n 5 77) auto-
BMT included SR patients autografted in CR1 after
TBI-containing regimen(s). Marrow was purged with
mafosfamide. There were no significant differences
in patient characteristics between the 2 groups.
Chao et al. [42] retrospectively studied the out-
comes of 50 adult (96% .15 years) patients treated
for AML (n 5 48) or biphenotypic acute leukemia
(n 5 2) at a single U.S. center with purged (n 5 30)
or unpurged (n 5 20) auto-BMT. BM was purgedwith 4-HC, and for the 2 biphenotypic acute leukemia
patients BM purging also included etoposide. Thirty-
four patients were in CR1, 12 in CR2, and 4 in first
relapse at time of transplantation. Median time from
CR1 to transplantation was 4 months. No significant
differences in patient characteristics between the 2
groups were reported.
Tandem versus Single
McMillan et al. [43] presented the results of a retro-
spective study of 82 adult (16-57 years) patients with
AML who underwent an unpurged auto-BMT. There
were 4 (5%) procedure-related deaths and 9 (11%) re-
lapses within 90 days of the first auto-BMT. Of the 69
remaining patients, 54 (78%) were eligible to proceed
to a second auto-BMT. Of these, 26 (48%) underwent
the second procedure. Reasons for not receiving the
second BMT included patient refusal (n5 22), toxicity
(n 5 4), infection (n 5 1), failed harvest (n 5 1), and
severe psychologic problems (n 5 1). The outcomes
of 25 patients who remained in remission at 90 days fol-
lowing the single auto-BMT were compared to those
patients who underwent the tandem auto-BMT. The
comparison single-graft group differed from the tan-
demBMTgroup in that the interval between remission
and auto-BMT was significantly longer (P5 .003).
Single-Arm Cohort Studies
The remaining11 studies, presentedonly inTable 7,
are single-arm, noncomparative studies examining
auto-BMT or auto-PBSCT: purging status not stated
(3 studies); purged auto-BMT (3 studies); unpurged
auto-BMT (3 studies); and unpurged auto-PBSCT
(2 studies).
ALLOGENEIC HSCT
This section provides descriptions of 22 allo-
HSCT studies, the outcomes of which are presented
in Table 8. Seven comparative studies examined the
impact on patient survival of related versus unrelated
allo-HSCT (n 5 2), T cell-depleted (TCD) versus T
cell-replete HSCT (n 5 3), and the use of BM versus
PBSC (n5 2). The remaining 15 studies represent sin-
gle arm, noncomparative studies of related and unre-
lated HSCT (n 5 6) and related allo-HSCT only
(n 5 9). Within each subsection, the highest quality
studies are presented first; studies of equal quality are
presented in descending order by sample size.
Related versus Unrelated
Hegenbart et al. [55] presented the results of a pro-
spective, multicenter study comparing related versus
unrelated donor allo-HSCT following reduced inten-
sity, TBI-based conditioning in 122 adult (17-74 years)
patients with AML. Patients were eligible for unre-
lated HSCT if they were.50 years old and for related
l)
/
/
/
)
Definition of
DFS/
EFS/
RFS/
LFS
(Interval)
% OS
(Signif)
S)
)
Not stated (2-yr OS)
48
48
(P 5 .68)
S)
8)
Not stated (2-yr OS)
32 overall
S)
)
Onset not stated;
events were
relapse or
death
Not stated
S)
71)
47)
57)
5 .002;
5 .24)
Not stated (5-yr OS)
62 (CI 50-74)
35 (CI 22-49)
58 (CI 53-62)
(P 1 versus 2 5 .001;
P 1 versus 3 5 .27)
S)
)
Not stated Not stated
S)
)
Time from SCT
to relapse
or death
(2-yr OS)
42 ± 6
38 ± 9
(P 5 .86)
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Reference No.
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients
by Study Group
Upper Limit
(Median)
Age at
Diagnosis
(Interval)
% TX -
Related
Mortality
Median
Follow-
up
(Interva
% DFS
% EFS
% RFS
% LFS
(Signif
Related versus Unrelated—Reduced-Intensity Conditioning (RIC)
Hegenbart et al.,
2006
[55]
21 Prospective
1998-2002
Multicenter (13)
Total n 5 122
Related donor 58
Unrelated donor 64
#74 yrs
(57.5 yrs)
(2-yr)
10
22
44 mos (2-yr DF
43
45
(P 5 .93
Sayer et al.,
2003
[56]
21 Retrospective
1998-2000
Multicenter (10)
Total n 5 113
Related donor 63
Unrelated donor 50
#67 yrs
(51 yrs)
(2-yr)
53 overall
1 yr (2-yr EF
39.9
16.7
(P 5 .02
T cell Depleted versus T Cell Replete
Wagner et al.,
2005
[57]
11 Prospective
Randomized
1995-2000
Multicenter (15)
Total n 5 405
AML n 5 101 (25%)
Total AML n 5 101
(ITT)
T cell depleted 48
T cell replete 53
Not stated
(31.2 yrs)
Not stated 4.2 yrs (3-yr DF
29
33
(P 5 .79
Hale et al.,
1998
[58]
211 Retrospective
Nonrandomized
Case-controlled,
1984-1995
Multicenter (3)
Total n 5 579
(1) in vitro and in vivo
T cell depleted 70
(2) in vitro T cell
depleted control 50
(3) IBMTR T cell
replete control 459
#56 yrs
(36 yrs)
(30 yrs)
(32 yrs)
(5-yr)
15
58
26
44 mos
116 mos
58 mos
(5-yr LF
60 (CI 47-
33 (CI 21-
52 (CI 47-
(P 1 versus 2
P 1 versus 3
Marmont et al.,
1991
[59]
21 Retrospective
IBMTR
Nonrandomized
1982-1987
Multicenter (137)
Total n 5 3211
AML n 5 1154 (62%)
AML CR1 n 5 717
Total AML CR1 n 5 717
T cell depleted 159
T cell replete 560
#56 yrs
(30 yrs)
(25 yrs)
Not stated Not
stated
(2-yr LF
45
57
(P\.02
PBSCT versus BMT
Garderet et al.,
2003
[60]
211 Retrospective EBMT
Registry
Nonrandomized Case-
controlled 1994-1999
Total n 5 213
AML n 5 111 (52%)
Total AML n 5 111
BM 73
PBSC 38
Not stated
92% adult
.16 yrs
(2-yr)
40
38
18 mos
25 mos
(2-yr LF
42 ± 6
33 ± 8
(P 5 .49
Definition of
DFS/
EFS/
RFS/
LFS
(Interval)
% OS
(Signif)
Not stated (2-yr OS)
65 ± 2
65 ± 3
(P 5 .94)
Time from BMT
to relapse
or death
(5-yr OS)
22 ± 4
)
Time from SCT
to relapse
or death
(2-yr OS)
81 (CI 67-95)
21 (CI 7-36)
(P\.001)
Not stated (5-yr OS)
41
)
Not stated Not stated
Not stated (4-yr OS)
39
FS) Not stated Not stated
Not stated (5-yr OS)
59 ± 2
)
)
)
)
Onset not stated;
events were
relapse or
death
(5-yr OS)
56 (CI 49-63)
60 (CI 51-67)
60 (CI 46-71)
(P not signif.)
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Reference No.
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients
by Study Group
Upper Limit
(Median)
Age at
Diagnosis
(Interval)
% TX -
Related
Mortality
Median
Follow-
up
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif)
Ringden et al.,
2002
[61]
21 Retrospective
EBMT Registry
Nonrandomized
Multicenter (224)
Total n 5 3465
AML n 5 2294 (44%)
AML CR1 n 5 1532
Total AML CR1
n 5 1532
BM 1072
PBSC 460
#65 yrs
(Mean)
(36 yrs)
(38 yrs)
(2-yr)
23
24
(Mean)
29 mos
15 mos
(2-yr LFS)
61 ± 2
57 ± 3
(P 5 .46)
Single Arm Cohort Studies—Related and Unrelated Allo-SCT
Michallet et al.,
2000
[62]
211 Retrospective SFGM
Registry 1980-1993
Advanced AML
Total n 5 397 #77 yrs
(28 yrs)
86% adult
.15 yrs
(5-yr)
45 ± 6
7.5 yrs (5-yr DFS)
20 ± 4
Stelljes et al.,
2005
[63]
211 Prospective
1999-2004
Multicenter (4)
RIC
Total n 5 71
In CR 36
Non-CR 35
#66 yrs
(51 yrs)
(2-yr)
8
37
25.9 mos (2-yr RFS)
78 (CI 63-93
16 (CI 3-29)
(P\.001)
Greinix et al.,
2002
[64]
21 Retrospective
1982-2000
Multicenter (4)
Total n 5 172 #55 yrs
(35 yrs)
(Not stated) 5.6 yrs (5-yr LFS)
40
Sierra et al.,
2000
[65]
21 Retrospective
1985-1998
Single center
Total n 5 161 #55 yrs
(30 yrs)
84% adult
$18 yrs
(5-yr)
43
2.9 yrs (5-yr LFS)
14 ± 2 (adults
Cook et al.,
2006
[66]
21 Retrospective
1989-2003
Multicenter (15)
CR1 after refractory
to first induction
Total n 5 68 \60 yrs
(36 yrs)
(Not stated)
38
. 4 yrs (4-yr DFS)
34
Bunjes et al.,
2002
[67]
21 Retrospective
Dates not stated
Single center
High-risk AML
Total n 5 57 #63 yrs
(45 ys)
(Not stated)
25
26 mos (Not stated, D
47
Single Arm Cohort Studies—Related Allogeneic SCT
Rocha et al.,
2002
[68]
21 Retrospective EBMT
Registry 1992-1999
Multicenter (4501)
Total n 5 572 #58 yrs
(35 yrs)
(5-yr)
24 ± 4
Not stated (5-yr LFS)
57 ± 2
Tallman et al.,
2000 [69]
21 Retrospective IBMTR
Nonrandomized
1989-1995
Multicenter (108)
Total n 5 431
Standard-dose Cy 222
High-dose Cy 147
No remission Tx 62
#56 yrs
(29 yrs)
(28 yrs)
(32 yrs)
(5-yr)
22
24
30
61 mos (5-yr LFS)
56 (CI 49-63
59 (CI 50-66
50 (CI 36-63
(P not signif.
nterval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif)
Definition of
DFS/
EFS/
RFS/
LFS
(Interval)
% OS
(Signif)
-yr RFS)
23
Time from BMT
to relapse
or death
Not stated
-yr EFS)
51 ± 5
Not stated (5-yr OS)
53 ± 5
-yr DFS)
(CI 21-43)
Time from BMT
to relapse
or death
Not stated
0-yr LFS)
60
10
ot stated)
Not stated Not stated
ot stated Not stated (5-yr OS)
71
ot stated Not stated (3-yr OS)
26 (CI 14-37)
ot stated Not stated (Not stated, OS)
50
40
(P not stated)
T, European Group for Blood and Marrow Transplan-
lapse-free survival; Signif., significance (probability); OS,
CI, 95% confidence interval.
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Reference No.
Quality
and
Strength
of
Evidence* Patient Population†
Number of Patients
by Study Group
Upper Limit
(Median)
Age at
Diagnosis
(Interval)
% TX -
Related
Mortality
Median
Follow-
up
(I
Clift et al.,
1992
[70]
21 Retrospective
1974-1990
Multicenter (3)
Untreated first relapse
Total n 5 126 #61 yrs
(.30 yrs)
75% adult
.18 yrs
(5-yr)
44
Not stated (5
Mehta et al.,
2002
[71]
21 Retrospective 1978-
1986
Single center
Total n 5 119 #51 yrs
(32 yrs)
(5-yr)
31 ± 4
9 yrs (5
Brown et al.,
1996 [72]
21 Retrospective
NAMTG
1984-1992
Multicenter
Resistant AML (40 in
untreated first relapse)
Total n 5 70 #53 yrs
(33 yrs)
(3-yr)
37 (CI 23-51)
Not stated (5
32
Greinix et al.,
1996
[73]
21 Retrospective
1982-1995
Single center
Total n 5 62
CR1 35
. CR1 27
#51 yrs
(32 yrs)
(10 yrs)
11
39
50 mos (1
(P n
Zikos et al.,
1998 [74]
21 Prospective
1990-1994
Single center
Total n 5 60 #50 yrs
(29 yrs)
(5-yr)
14
4.4 yrs N
Bibawi et al.,
2001
[75]
21 Retrospective
1991-1998
Single center
Total n 5 62
AML n 5 50 (81%)
Advanced AML
Total n 5 50 #59 yrs
(37 yrs)
(100 d)
19
3 yrs N
Frassoni et al.,
1991
[76]
22 Retrospective
1981-1989
Single center
Total n 5 168
AML n 5 118 (63%)
Total n 5 118
CR1 88
Advanced Disease 30
Not stated Not stated 767 days N
*Quality and strength of evidence definitions are listed in Table 1.
†AML indicates acute myelogenous leukemia; BMT, bone marrow transplantation; SCT, stem cell transplantation; CR, complete remission; EBM
tation; IBMTR, International BoneMarrowTransplant Registry; ITT, intent-to-treat; DFS, disease-free survival; EFS, event-free survival; RFS, re
overall survival; ctrl grp, control group; NAMTG, North American Marrow Transplant Group; SFGM, Societe Franc¸aise de Greffe de Moelle;
The Role of Cytotoxic Therapy with HSCT 165HSCT if they were .55 years old. Younger patients
were included if they had comorbid conditions that
excluded them from standard conditioning for allo-
HSCT. Eighteen patients had secondary AML, 51
were in CR1, 39 were in CR2, and 32 had more
advanced AML. Patients received either a related
(n 5 58, 47.5%) or unrelated (n 5 64, 52.5%) donor
allo-HSCT. Median time from last chemotherapy to
SCT was 76 days, with no difference between the 2
groups. Patient characteristics were comparable be-
tween the 2 groups except more related than unrelated
donor allo-recipients were in CR1 (55% versus 30%),
and more unrelated than related recipients had under-
gone a previous auto-HSCT (23% versus 3%).
Sayer et al. [56] reported the results of a multicen-
ter, retrospective analysis of 113 adult (16-67 years) pa-
tients with AMLwho received either a matched related
donor (n 5 63) or matched unrelated donor (n 5 50)
allo-SCT following RICwith fludarabine and busulfan
(Flu 1 Bu, n 5 93) or TBI (n 5 20). Stem cell source
was PBSC (n 5 102), BM (n 5 10), or both (n 5 1).
Differences in patient characteristics between the 2
groups were not reported.
T Cell Depleted (TCD) versus T Cell Replete
Wagner et al. [57] presented the outcomes of 103
adult (77%.18 years) patients with AML randomized
to undergo an unrelated allo-BMT with either TCD
marrow and cyclosporine (n 5 48) or a T cell-replete
BMT with methotrexate (MJX) and cyclosporine
(n 5 53). Two methods of TCD were used: counter-
flow centrifugal elutriation, a physical method of
separating T cells; and T10B9, an antibody. Although
prognostic factors were similar between the 2 random-
ized groups, there were differences by age, race, and
total nucleated cell dose among centers differentiated
by the 2 methods of TCD.
Hale et al. [58] presented the results of a retrospec-
tive, case-controlled study of adult (14-56 years) pa-
tients with AML in CR1, comparing TCD versus T
cell-replete marrow in HLA-matched sibling allo-
BMT. CAMPATH-1M (CAM-IgM) was used for in
vitro depletion of the graft and CAMPATH-1G
(CAM-IgG) for in vivo depletion of the recipient prior
to graft infusion (n 5 70). The results were compared
with 2 control groups: (1) a historic group of 50 pa-
tients who received CAM-IgM depleted BM, but no
in vivo CAM-IgG; and (2) a matched group of concur-
rently treated patients (n 5 459) who received T cell-
replete allo-BMT and were reported to the IBMTR.
No differences in patient characteristics among the
groups were reported.
Marmont et al. [59] analyzed the effects of TCD
on the outcome of HLA-matched sibling donor BMT
in a multicenter, retrospective study of 1154 adult
(#56 years) patients with AML from 137 centers thatreported to the IBMTR. A total of 245 AML patients
received a TCD allo-BMT. A variety of TCD tech-
niques were used by the centers, including physical,
broad antibody, anti-T and NK, and anti-T. During
the same time period, 909 control group patients re-
ceived anon-TCDallo-BMT.Nodifferences inpatient
characteristics between the 2 groups were reported.
PBSCT versus BMT
Garderet et al. [60] presented the results of a retro-
spective, case-controlled study of 111 adult (92%.16
years) patients with AML reported to the EBMT,
comparing PBSC versus BM as the stem cell source.
The data from 38 AML patients who received G-
CSFmobilized PBSC from amatched unrelated donor
were compared with a historic control group of 73
matched unrelated allo-BMT patients computer-
matched on disease status at transplant, age, year of
transplant, and whether or not the graft was TCD.
Ringden et al. [61] reported the results of a retro-
spective comparison of BM (n 5 1537) versus PBSC
(n 5 757) as the stem cell source in 2294 adult
(16-65 years) patients with AML who underwent an
HLA-matched sibling HSCT and were reported to
the EBMT Registry. Patient characteristics between
the 2 groups were comparable, except patients receiv-
ing PBSC were older, had older donors, received more
TCD grafts, and received methotrexate (MTX) and
TBI less frequently than patients receiving BM.
Single-Arm Cohort Studies
The remaining 15 studies, presented only in Table
8, examined the outcomes of single arm, noncompara-
tive studies of related and unrelated allo-HSCT (n5 6)
and related allo-HSCT only (n 5 9). No single-arm
unrelated allo-HSCT studiesmet the inclusion criteria
for this review.
COMPARISON OF TREATMENT REGIMENS
Although the term ‘‘conditioning regimen’’ is often
applied to the treatment immediately prior to allo- or
auto-HSCT, in this review it is used only in relation
to allo-HSCT, as conditioning regimen implies treat-
ment that includes facilitation of engraftment of alloge-
neic cells. In this review, the term ‘‘high-dose therapy
regimen’’ is used to refer to the treatment immediately
prior to auto-HSCT. This section provides descrip-
tions of 14 studies comparing treatment regimens and
their impact on HSCT outcomes, which are presented
in Table 9. These studies included high-dose auto-
HSCT (n 5 2), myeloablative (n 5 8), or RIC (n 5 4)
allo-SCT (n5 12), and 1 study that did not differenti-
ate between auto-and allo-SCT (presented in text
only).Within each subsection, the highest quality stud-
ies are presented first; studies of equal quality are pre-
sented in descending order by sample size.
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Reference No.
Quality and
Strength of
Evidence* Patient Population†
Number of Patients by
Study Group
Upper Limit
(median)
Age at Diagnosis
(Interval)
% TX -Related
Mortality
Median
Follow-up
(I
Autologous SCT—Comparison of 2 or More High-Dose Therapy Regimens
Ringden et al.,
1996
[77]
21 Retrospective
EBMT Registry
Nonrandomized
1987-1994
Multicenter
Total n 5 660
Bu 1 Cy 330
Cy 1 TBI 330
.40 yrs
(Not stated)
(2-yr)
12 ± 2
15 ± 2
Not stated (2
(P n
Ball et al.,
2000
[78]
21 Retrospective
Nonrandomized
1984-1997
Multicenter (13)
Total n 5 138
Bu 1 Cy 93
Cy 1 TBI 35
Bu 1 VP-16 10
\65 yrs
(40 yrs)
Not stated Not stated (2
(P n
Allogeneic SCT—Comparison of 2 or More Myeloablative Conditioning Regimens
Blaise et al.,
1992
[79]
11 Prospective
GEGMO
Randomized
1987-1990
Multicenter (15)
Total n 5 101
Bu 1 Cy 51
Cy 1 TBI 50
Not stated
(31 yrs)
(32 yrs)
(2-yr)
27
8
(mean)
23 mos
(2
(
Ringden et al.,
1999
[80]
11 Retrospective
Randomized
1988-1992
Multicenter (6)
AML n 5 69 (41%)
Total n 5 69
Bu 1 Cy 37
Cy 1 TBI 32
#68 yrs
(35 yrs)
(34 yrs)
(7-yr)
(Overall)
34
14
Not stated (2
(
Farag et al.,
2005
[81]
211 Retrospective
Nonrandomized
1984-2001
2 centers
Total n 5 237
Bu 1 Cy 1 VP-16 127
Bu 1 Cy 110
#62 yrs
(40 yrs)
(35 yrs)
(Day 1100)
26.8
21.8
4.3 yrs
10.9 yrs
N
Resbeut et al.,
1995
[82]
211 Prospective
SFGM
Nonrandomized
1983-1990
Multicenter (17)
Total n 5 171 (ITT)
Cy 1 Fractionated
TBI 106
Cy 1 Single dose
TBI 65
(Not stated)
(29 yrs)
(25.7 yrs)
24
38
63 mos (5
56
43
(
Litzow et al.,
2002
[83]
21 Retrospective
Nonrandomized
IBMTR
1988-1996
Multicenter (350)
Total n 5 581
Bu 1 Cy 381
Cy 1 TBI 200
#57 yrs
(35 yrs)
(34 yrs)
(5-yr)
27
30
55 mos
45 mos
(5
54
58
(
(Interval)
% DFS/
% EFS/
% RFS/
% LFS
(Signif)
Definition of
DFS/
EFS/
RFS/
LFS
(Interval)
% OS
(Signif)
2-yr LFS)
64 ± 3
66 ± 3
not signif.)
Not stated Not stated
ot stated Not stated (5-yr OS)
73
41
(P\.0009)
5-yr LFS)
(CI 10-58)
(CI 34-68)
(P 5 .053)
Onset not stated;
events were
relapse
or death
(5-yr OS)
38 (CI 15-61)
51 (CI 36-66)
(P 5 .149)
2-yr DFS)
(CI 29-60)
(CI 24-62)
(CI 25-72)
not signif)
Time from BMT
to relapse
or death
(2-yr OS)
50 (CI 34-66)
47 (CI 30-65)
49 (CI 24-74)
(P not signif)
2-yr LFS)
44 ± 3
40 ± 3
(P 5 .80)
Not stated (2-yr OS)
46 ± 3
47 ± 3
(P 5 .43)
3-yr PFS)
32
19
not stated)
Not stated (3-yr OS)
35
30
(P not signif.)
n; EBMT, European Group for Blood and Marrow
vival; RFS, relapse-free survival; Signif., significance
% confidence interval.
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Reference No.
Quality and
Strength of
Evidence* Patient Population†
Number of Patients by
Study Group
Upper Limit
(median)
Age at Diagnosis
(Interval)
% TX -Related
Mortality
Median
Follow-up
Ringden et al.,
1996
[77]
21 Retrospective
EBMT Registry
Nonrandomized
1987-1994
Multicenter
Total n 5 446
Bu 1 Cy 223
Cy 1 TBI 223
.40 yrs
(Not
stated)
(2-yr)
16 ± 3
19 ± 3
Not stated (
(P
Bacigalupo et al.,
2000
[84]
21 Retrospective
Non-randomized
1980-1998
Single center
Total n 5 150
Cy 1 TBI $ 9.9 Gy 116
Cy 1 TBI\ 9.9 Gy 34
#47 yrs
(28 yrs)
(5-yr)
18
26
2467 days N
Schapp et al.,
1997
[85]
21 Retrospective
Nonrandomized
1981-1995
Single center
Total n 5 181
AML n 5 70 (39%)
Total AML n 5 70
Cy 1 TBI 29
Cy1TBI1DNRor Ida
41
#59 yrs
(Overall)
(32 yrs)
(36 yrs)
(Not
stated)
26
22
63 mos (
34
51
Allogeneic SCT—Reduced-Intensity Conditioning (RIC) Regimens
Shimoni et al.,
2006
[86]
211 Prospective
Nonrandomized
No dates given
(5 years)
Single center
AML/MDS (85%
AML)
Total n 5 112 (ITT)
Cy 1 Bu 45
RIC Flu 1 Bu2 41
Modified ablative
Flu 1 Bu4 26
#70 yrs
(50 yrs)
(57 yrs)
(51 yrs)
(2-yr)
10
3
2
22 mos (
45
43
49
(P
Aoudjhane et al.,
2005
[87]
21 Retrospective
EBMT Registry
Nonrandomized
1997-2003
Multicenter (182)
Total n 5 722
Myeloablative 407
RIC 315
$50 yrs
(54 yrs)
(57 yrs)
(2-yr)
32
18
13 mos
14 mos
(
de Lima
et al., 2004
[88]
21 Retrospective
Nonrandomized
1995-2000
Single center
AML/MDS (72%
AML)
Total n 5 94
Flu 1 Mel 62
Flu 1 Cy 32
#75 yrs
(54 yrs)
(61 yrs)
(3-yr)
39
16
40 mos (
(P
*Quality and strength of evidence definitions are listed in Table 1.
†AML indicates acute myelogenous (myeloid) leukemia; BMT, bone marrow transplantation; SCT, stem cell transplantation; CR, complete remissio
Transplantation; IBMTR, International Blood and Marrow Transplant Research; ITT, intent-to-treat; DFS, disease-free survival; EFS, event-free sur
(probability); OS, overall survival; SFGM, Societe Franc¸aise de Greffe de Moelle; GEGMO, Groupe d’Etude des Greffes de Moelle Osseuse; CI, 95
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Ringden et al. [77] reported the outcomes of
660 adult (79% .20 years) patients with AML in
CR1 who underwent auto-SCT after treatment with
Bu 1 Cy (n 5 330) or Cy 1 TBI (n 5 330) and were
reported to the EBMT Registry. Significantly more
patients treated with Bu 1 Cy were in first relapse,
and patients in the Cy 1 TBI group were more likely
to bemale and in CR2. Figure 6 compares the actuarial
LFS between patients receiving Bu 1 Cy versus Cy 1
TBI prior to auto-SCT.
Ball et al. [78] reported the results of a retrospective,
nonrandomized, multicenter study of 138 adult (#67
years) patients with AML comparing 3 high dose ther-
apy regimens followed by auto-BMT. The treatment
regimen prior to 1988 was Cy 1 fractionated TBI
(n5 35), post-1988 it was changed toBu1Cy (n5 93),
and10patients at 1 center (post-1988)were treatedwith
Bu 1 VP-16. No differences in patient characteristics
among the 3 groups were reported. In all, 110 patients
were in CR (CR1, n 5 23; CR2/3, n 5 87) and 28
were in first relapse at the time of transplantation.
Allogeneic HSCT
Myeloablative conditioning regimens. Blaise et al. [79]
presented the results of a prospective, randomized
study by the Groupe d’Etudes de la Greffe de Moelle
Osseuse (GEGMO) of 101 adult (.14 years) patients
with AML in CR1 conditioned prior to an HLA-
matched sibling donor allo-HSCT with either Bu 1
Cy (n 5 51) or Cy 1 TBI (n 5 50). Sixty three
(62%) patients (Cy 1 TBI, n 5 31; Bu 1 Cy, n 5 32)
were transplanted \120 days after diagnosis. There
were no statistical differences in patient characteristics
between the 2 groups.
Figure 6. Actuarial LFS in autograft recipients with AML in CR1
treated with Bu/Cy (broken line) (n 5 330) or Cy/TBI (solid line)
(n 5 330). The survival curves are not significantly different (P 5
.64). (Reprinted with permission; [77].)Ringdenetal. [80]reportedtheresultsofa retrospec-
tive analysis of 69 adult (#55 years) patients with AML
inCR1 (n5 51) or in$CR2 or early relapse (n5 18) in
a randomized trial comparing Bu1 Cy (n5 37) versus
Cy 1 TBI (n 5 32) followed by an HLA-matched
sibling donor allo-BMT. There were no differences in
patient characteristics between the 2 groups.
Farag et al. [81] presented theoutcomes of 237 adult
(17-62 years) patients with AML in a retrospective,
nonrandomized study comparing Bu 1 Cy 1 VP-16
(n 5 127) versus Bu 1 Cy (n 5 110) followed by
allo-HSCT from HLA-matched related or unrelated
donors. Patients who received Bu 1 Cy 1 VP-16
were significantly more likely to be older, have high-
risk disease, and to receive a matched-unrelated donor
allo-HSCT than the patients in the Bu1 Cy group.
Resbeut et al. [82] reported the results of a prospec-
tive study by the Societe Franc¸aise de Greffe deMoelle
(SFGM) of 171 adult (median age5 27 years) patients
with AML in CR1 who were nonrandomly assigned to
Cy 1 single dose TBI (10 Gy) (n 5 65) or Cy 1 frac-
tionated TBI (range 10-15 Gy; 76% received 12 Gy in
6 fractions over 3 days) (n 5 106) prior to undergoing
an HLA-matched sibling allo-BMT. Patient charac-
teristics were comparable between the 2 groups except
for a shorter diagnosis-to-BMT interval in the frac-
tionated TBI group.
Litzow et al. [83] presented the outcomes of 581
adult (20-57 years) patients with AML in CR1 in a ret-
rospective, nonrandomized, IBMTR study comparing
Bu 1 Cy versus Cy 1 fractionated TBI (dose .11.25
Gy) conditioning regimens followed byHLA-matched
sibling allo-HSCT. Significantly more patients in the
Bu1 Cy group were.40 years, and a higher percent-
age of Cy1TBI patients required more than 1 cycle of
chemotherapy to achieve CR1.
Ringden et al. [77] reported the outcomes of 446
adult (79% .20 years) patients with AML in CR1
who underwent allo-HSCT following conditioning
with Bu 1 Cy (n 5 223) or Cy 1 TBI (n 5 223) and
were reported to the EBMT Registry. Significantly
more patients treated with Bu 1 Cy were in first re-
lapse, and patients in the Cy 1 TBI group were
more likely to be male and in CR2. Figure 7 compares
the actuarial LFS between patients receiving Bu 1 Cy
versus Cy 1 TBI prior to allo-HSCT.
Bacigalupo et al. [84] presented the results of a ret-
rospective, nonrandomized study of 150 adult (#47
years) patients with AML in CR1, comparing condi-
tioning with Cy 1 low dose TBI (\9.9 Gy, n 5 34)
versus Cy 1 high dose TBI ($9.9 Gy, n 5 116) prior
to HLA-matched related donor allo-BMT. There
were no significant differences in patient characteris-
tics between the 2 groups.
Schapp et al. [85] reported the results of a retro-
spective, nonrandomized study of 70 adult (13-59
years) patients with AML in CR1 who underwent
The Role of Cytotoxic Therapy with HSCT 169conditioning with Cy1 TBI (n5 29) or Cy1 TBI1
DNR or Ida (n 5 41) followed by an HLA-matched
sibling donor allo-HSCT. No significant differences
in patient characteristics between the 2 groups were re-
ported.
Reduced-intensity conditioning regimens. Shimoni et al.
[86] presented the outcomes of 112 adult (17-70 years)
patients with AML (n 5 95) or MDS (n 5 17) in CR1
enrolled in a prospective, nonrandomized study com-
paring standard myeloablative conditioning with Cy
1 Bu (12.8 mg/kg) (n 5 45) versus RIC with Flu 1
Bu (6.4 mg/kg, FluBu2, n5 41) or a modified myeloa-
blative conditioning regimen with Flu 1 Bu (12.8
mg/kg, FluBu4, n 5 26) followed by matched or
mismatched, related or unrelated allo-SCT. Older pa-
tients (.65 years) were more likely to receive FluBu2
conditioning, patients with active disease were more
likely to receive FluBu4 conditioning.
Aoudjhane et al. [87] reported the results of a retro-
spective, nonrandomized study of 722 adult (.50
years) patients with AML reported to the EBMT
Registry who underwent an HLA-matched sibling
allo-SCT, comparing RIC (n 5 315) with Flu 1
low-dose TBI (\3 Gy), Bu (#8 mg/kg), or other non-
myeloablative drugs versus myeloablative condition-
ing (n 5 407) with TBI (.10 Gy) or Bu (.8 mg/kg)
1 other myeloablative drugs. RIC patients were older
and more likely to be male than patients who received
a myeloablative (MA) conditioning regimen. Figure 8
compares the unadjusted cumulative incidence of
LFS between the RIC and MA cohorts.
de Lima et al. [88] reported the outcomes of
94 adult (22-75 years) patients with AML (n 5 68)
or high-risk MDS (n 5 26) in a retrospective,
nonrandomized study comparing a nonmyeloablative
regimen of Flu1Cy1 Ida (FAI, n5 32) versus a mye-
losuppressive, RIC regimen of Flu1Mel (FM, n5 62)
prior to HLA-matched related or unrelated donor
Figure 7.ActuarialLFSinallograft recipientswithAMLinCR1treated
with Bu/Cy (n 5 223) or Cy/TBI (n 5 223). Survival curves are not
significantly different (P5 .63). (Reprinted with permission; [77].)allo-SCT. Compared to patients who received FM,
those treated with FAI were significantly older and
more likely to be in CR1 at transplant.
Kroger et al. [89] reported the results of a prospec-
tive, nonrandomized study of 90 adult (#64 years)
patients with AML comparing Bu 1 Cy 1 low dose
VP-16 (30 mg/kg) (n 5 60) versus Bu 1 Cy 1 high
dose VP-16 (45 mg/kg) (n 5 30) followed by auto-or
allo-HSCT (HSCT type not differentiated; outcomes
are presented only in the text, not in Table 9). Stem
cell sources were allo-related BM (n 5 53), allo-unre-
lated BM (n5 5), allo-unrelated PBSC (n5 2), synge-
neic BM (n 5 2), auto-purged BM (n 5 9),
auto-unpurged BM (n 5 9), or auto-PBSC (n 5 10).
Differences in patient characteristics between the 2
conditioning regimens were not reported. Median
follow-up was 16 months. Two-year treatment-related
mortality (TRM) was 16% versus 26%, 3-year DFS
was 62% versus 40% (P 5 .03), and 3-year OS was
63% versus 41% (P 5 .06) for patients receiving
low-versus high-dose VP-16, respectively.
TREATMENT FOR RELAPSE AFTER FIRST ALLO-HSCT
This section presents 2 studies of treatment for
relapse after an initial allo-HSCT, 1 using donor
lymphocyte infusion (DLI) and the other a second
allo-HSCT. Although these studies may not meet all
criteria for inclusion, they were included in this review
to illustrate the typical outcome of these treatments for
adult AML patients. Study designs and outcomes are
presented in the text.
DLI
Collins et al. [90] reported the results of a retro-
spective study of 46 adult (median age 33.5 years) pa-
tients with AML who received a DLI to treat relapse
after a related (n 5 44) or unrelated (n 5 2)
Figure 8.Unadjusted cumulative incidence of LFS for patients over
50 years of age with AML receiving myeloablative (MA) versus re-
duced intensity conditioning (RIC) prior to HLA-identical sibling
HSCT. (Reprinted with permission; [87].)
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sponse to DLI because of prior chemotherapy. Of
the remaining 39 patients, 6 (15.4%) achieved CR.
Median follow-up of survivors after DLI was 506
days. An OS value was not provided; however, a Ka-
plan-Meier curve indicated a 3-year OS of approxi-
mately 15%.
Second Allogeneic SCT
Eapen et al. [91] presented the outcomes for 125
adult (overall, 66% .21 years) AML patients from
the IBMTR who received a second allo-SCT for
recurrent or persistent leukemia after initial HLA-
matched sibling SCT. Overall, 85% of the patients
received allografts from the same donor for both trans-
plants. Median follow-up of survivors was 93 months.
The 3-year LFS and OS were both 27% (95% CI,
19%-35%).
AUTO-SCT AS TREATMENT OF THERAPY-RELATED
OR SECONDARY AML
The following 2 studies examined auto-SCT as
treatment for secondary AML after MDS or therapy-
related AML.
De Witte et al. [92] reported the outcomes of 60
adult patients (median age 39 years), retrieved from
the registries of the Chronic and Acute Leukemia
Working Parties of the European Group for Blood
and Marrow Transplantation, who underwent an auto-
BMT in CR1 for secondary (n5 39) or therapy-related
MDS/AML (n 5 21). The median interval between
diagnosis and auto-BMT was 7 months. Median fol-
low-up of survivors was 10 months. For secondary
AML and therapy-related MDS/AML patients, 2-year
OS from BMT was 34% and 41%, DFS was 30% and
36%, and TRM was 5% and 10%, respectively.
Kro¨ger et al. [93] reported the results of 65 adult
(median age 39 years) patients with therapy-related
MDS/AMLwho underwent an auto-SCT and were re-
ported to theEBMT.Stemcell sourcewasBM(n5 31),
PBSC (n5 30), or a combination of both (n5 4). The
median time between diagnosis and transplant was 5
months. Median follow-up was not reported. Two-
year TRM was 12% (95% CI, 6%-38%) and 3-year
DFS and OS from BMT were 32% (95% CI,
18%-45%)and35%(95%CI, 21%-49%), respectively.
LATE EFFECTS AND QUALITY OF LIFE
Late Effects
The following studies investigated late effects in
adult patients who underwent auto- or allo-SCT for
treatment of AML, providing additional insight into
the potential outcomes related to specific treatments.
Frassoni et al. [94] investigated the occurrence of
late events in patients with AML who underwent
allo-HSCT (n 5 1059) or auto-BMT (n 5 656).They found that the incidence of late relapse continu-
ously decreased with time. Patients with no recurrence
at 2 years had an 82% chance of remaining in CR at 9
years following transplantation. The latest relapses
were observed following allo-HSCT at 6.6 years for
patients transplanted in CR1, as opposed to 3.7 years
for patients transplanted in CR2, and following
auto-HSCT at 6 years and 5.1 years, respectively.
Compared to auto-SCT, patients who underwent
allo-HSCT experienced a lower frequency of late
relapse.
Abdallah et al. [95] analyzed the long-term out-
comes and toxicities of 98 high-risk AML patients in
CR1 or CR2 treated with TBI and high-dose Cy prior
to auto-SCT purged with mafosfamide. Long-term
complications (median observation period of 11.67
years) included cataracts (44.4%), HCV infections
(5%), cardiac complications (4%), MDS (4%), and
renal insufficiency (2%).
Wadleigh et al. [96] conducted a retrospective
study of 62 patients who underwent allo-HSCT for
the treatment of AML or AML arising from MDS to
determine whether gemtuzumab ozogamicin (GO),
a monoclonal antibody (mAb) used in the treatment
of AML, increased the risk of veno-occlusive disease
(VOD). Nine of 14 (64%) of patients who received
GO prior to allo-SCT developed VOD compared
to 4 (8%) of 48 patients without prior GO exposure
(P\ .0001).
Toor et al. [97] investigated life-threatening bleed-
ing associated with platelet transfusion refractoriness
among 39 patients who underwent high-dose chemo-
radiotherapy followed by sibling donor allo-BMT
(n 5 12) or auto-BMT (n 5 27). Increased platelet
requirements in HLA alloimmunized auto-BMT pa-
tients were observed at a median of 211 platelet trans-
fusions versus 0 transfusions in nonalloimmunized
auto-BMT patients (P \ .01) and 17 in allo-BMT
patients. Five of 6 HLA alloimmunized auto-BMT pa-
tients experienced delayed bleeding, which contrib-
uted to their death while still in CR.
Butt and Clark [98] studied the iron status of 32
adult AML patients enrolled in the MRC AML 10
and 12 trials and found that patients who underwent
auto-SCT had a higher median first serum ferritin
level (3245 mg/L) than patients who received chemo-
therapy alone (1148 mg/L) or allo-SCT (1334 mg/L)
because of increased use of transfused blood. Nine of
the 10 auto-SCT recipients underwent venisection,
but no patient suffered end organ damage.
Quality of Life (QOL)
The following studies investigated the QOL re-
ported by or observed in patients who underwent
allo- or auto-SCT for the treatment of AML.
The Role of Cytotoxic Therapy with HSCT 171Watson et al. [99] surveyed 481 patients 1 year
from the end of treatment in the MRC AML 10 trial
to compare QOL following allo-BMT (n 5 97),
auto-BMT (n 5 74), or chemotherapy (n 5 310). On
the EORTC Quality of Life-Core 30 Questionnaire
(QLQ-C30) with 5 functional scales (physical, role,
cognitive, emotional, and social) and a leukemia-spe-
cific measure (QLQ-LEU) designed to assess late ef-
fects of BMT, allo-BMT was found to have
a significantly adverse impact on most QOL dimen-
sions compared to auto-BMT or chemotherapy.
Zittoun et al. [100] studied the self-reported QOL
of 98 patients in continued CR for 1-7.4 years after
undergoing allo-BMT, auto-BMT, or ICC in the
EORTC-GIMEMA AML 84 trial. On all parameters,
including somatic symptoms (mouth sores, cough, hair
loss, headache), repeated acute medical problems,
physical functioning, role functioning, leisure activi-
ties, sexual functioning, overall physical condition,
and overall QOL, there were significant differences
among the 3 groups with a consistent ranking of
allo-BMT lower than auto-BMT and auto-BMT
lower than chemotherapy.
Hsu et al. [101] used the EORTC QLQ-C30, as
well as the World Health Organization QOL ques-
tionnaire (WHOQOL-BREF), to examine differences
in QOL between 41 AML patients who underwent
allo-BMT as consolidation or salvage therapy versus
63 patients who received traditional chemotherapy
alone. The mean scores on the 2 QOL questionnaires
did not differ significantly between the 2 groups; how-
ever, when comparing survival-weighted psychometric
scores (SWPS), patients who underwent allo-BMT
had significantly (P\ .01) higher SWPS on all func-
tioning domains and symptom items of the QLQ-
C30 and all 4 domains (physical, psychologic, social,
and environmental) of the WHOQOL-BREF than
those who received chemotherapy only.
Wellisch et al. [102] found no significant differ-
ences in QOL between AML patients who underwent
BMT (n5 11) or chemotherapy only (n5 27), with re-
gard to occurrence of depressive symptoms, multifocal
psychiatric symptomatology, or on any subscale of the
CARESQuestionnaire, a 139-item inventory designed
to evaluate the problems and rehabilitation needs of
patients with cancer.
PROGNOSTIC FACTORS
Table 10 presents a summary of patient and disease
prognostic factors and their reported effect on survival
outcomes as determined by multivariate analysis in
adult AML studies. Atlhough many of the referenced
studies in Table 10 were described in the text and
tables of this review, others were specifically prognos-
tic factor studies [references in brackets] that are not
presented in this evidence-based review because theydid not meet the inclusion criteria. Studies were not
included in this table if the study did not conduct
a multivariate analysis and/or if transplantation was
not an included treatment modality. The data in this
table are provided for the reader’s information and
were not used to make treatment recommendations.
FUTURE DIRECTIONS
Areas of Needed Research
After reviewing the evidence, the panel recommen-
ded that large clinical trials be conducted to investigate
the following important areas of needed research in
adult onset AML: (1) What is the role of HSCT in
treating patients with specific molecular markers (eg,
FLT3, NPM1, CEBPA, BAALC, MLL, NRAS, etc.)
especially in patients with normal cytogenetics? (2)
What is the benefit of using SCT to treat different
cytogenetic subgroups? (3) What is the impact on sur-
vival outcomes of reduced intensity or nonmyeloabla-
tive versus conventional conditioning in older (.60
years) and intermediate (40-60 years) aged adults? (4)
What is the impact on survival outcomes of unrelated
donor SCT vesus chemotherapy in younger (\40
years) adults with high risk disease?
Ongoing Studies
Several studies are summarized below that address
areas of needed research or other critical issues that
may affect the treatment recommendations made in
Table 3. These studies are currently accruing patients
and/or have been published in abstract form.
Effect of specific molecular markers on outcome in AML pa-
tients with normal cytogenetics. Schlenk et al. [142] evalu-
ated the prognostic value of NPM1, FLT3, CEBPA,
MLL, and NRAS gene mutations on RFS and OS fol-
lowing allo-SCT in adult (16-60 years) AML patients
with normal cytogenetics. Between 1993 and 2004,
872 patients with normal cytogenetics were entered
on 4 AMLSG treatment trials [AML-2/95, AML-1/
99, AML HD93, AML HD98A]. In all 4 trials there
was a biologic allocation to an MRD allo-SCT in
CR1. The median age of patients was 48 years; median
follow-up time was 49 months. Of 666 patients achiev-
ing a CR after induction therapy, 171 had a MRD and
143 (84%) of these received an allo-HSCT in CR1.
Subgroup analyses were performed on an ITT basis
by mutation status (NPM11/FLT3-internal tandem
duplication [ITD] versus all other combinations),
which revealed a significant improvement in RFS
(HR 5 0.56, 95% CI 0.39-0.81) and OS (HR 5 0.69
(95% CI 0.48-0.98) in the subgroup of patients with-
out the NPM11/FLT3-ITD marker constellation
who received an allo-SCT in CR1.
Dose intensity prior to auto-SCT. The EORTC and
GIMEMA Leukemia Cooperative Groups have
sponsored a phase III randomized, international,
Studies
References Reporting No Significant Impact of
Prognostic Factor on Survival Outcome
,15,24,35,39,41,46,49-51,63,64,74,75,[117-119],[129]
,19,24,32,40,41,45,49,58,[106],[113],[116],[117],[125],[129]
,55,63
,40,45,46,[117],[119],[125],[129]
,15,24,26,35,40,41,49,50,[106],[116]
,44,75
,19,26,39,[117]
,40
17]
,41
,40,41,46,51,[106]
,49,56,74,75,[124]
17]
, 58, 59,[106]
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Prognostic Factor†
References Reporting Significant Impact of
Prognostic Factor on Survival Outcome
Patient Characteristics
Age 19,20,27,28,32,37,40,45,47,55,57,58,62,68,
69,71,[103],‡[104-116],[125],[127],[128],[131-135],[137],[139]
10-12
Sex 15, 69,[104],[118] 11,12
Disease Characteristics at Diagnosis
AML type (de novo or secondary) [114],[126],[134],[135] 15,26
WBC count 10,11,19,20,30,49,50,[104],[112],[114],[116],[118],[120],
[125],[127],[130],[133],[134],[137],[139]
12,39
FAB subtype 28-30,37,61,68,[105],[113],[114] 11,12
Performance status 56,57,69,[109],[116],[118],[121] 11,40
Cytogenetic risk group/Karyotype 11,15,18,19,26,29,30,39,45,49,50,55,57,66, 68,[104],
[105],[107],[110],[112-114],[116],
[117],[122-124],[129],[131],[132],[134],[135],
[137],[138],[141]
10,40
Molecular markers (eg, FLT3,§ BAALC, CEBPA,
NPM1, ERG, etc.)
[107],[125-136]
Flow cytometric cell surface expression (eg, CD2,
CD34, CD36, CD56, etc.)
[131],[137-141]
CMV status 29,57 63
Hepatomegaly/Splenomegaly 15 [116]
Extramedullary disease 40
Disease Characteristics at SCT
No. cycles to achieve CR1 10,45,50,66 11,12
Time to CR1 24,35
Duration of CR1 27,40,51,65
Time from diagnosis to CR1 37,[106] 41,46
Time from diagnosis to SCT 28,66,[108] 74,[1
Time from CR1 to stem cell harvest 12,40
Time from CR1 to SCT 37,[105],[115] 12,19
Disease status at SCT 29,55,60-65,72,[109],[114] 32,41
% BM blasts at SCT 56,[104],[109],[121] 15,[1
Year of Transplant 46,49,64,69,[113] 40, 41
*Survival 5 any one or more of the following: OS, DFS, RFS, LFS, EFS, PFS (see other tables for explanation of abbreviations).
†Factors were not included if the study did not conduct a multivariate analysis and/or if transplantation was not an included treatment mod
‡Bracketed [ ] references indicate prognostic factor studies that are not described in the text of the evidence-based review.
§Only FLT3-ITD has been shown to have prognostic significance, other FLT3 mutations have unknown significance.
The Role of Cytotoxic Therapy with HSCT 173multicenter, prospective study (Protocol ID:
EORTC-1992.00) of adult (15-60 years) patients
with AML, comparing high-dose versus standard
dose induction therapy (Ara-C1DNR1VP-16), fol-
lowed by consolidation and auto-PBSCT or BMT
with or without interleukin-2.
Dose intensity and in vivo purged vs unpurged auto-PBSCT.
The ECOG has sponsored a phase III randomized,
multicenter, prospective trial (Protocol ID: ECOG-
1900) in adult (16-60 years) patients with AML, com-
paring survival outcomes after high or standard dose
DNR 1 Ara-C followed by in vivo purged (with gem-
tuzumab ozogamicin) versus unpurged auto-PBSCT.
Patients with appropriate donors are biologically
assigned to allo-SCT.
Comparison of allo-SCT conditioning regimens. The
Fred Hutchinson Cancer Research Center (FHCRC)
has sponsored aphase III, randomized,multicenter, pro-
spective study (Protocol ID: FHCRC-1992.00) of adult
(#65 years) patients with AML or MDS, comparing
survival outcomes after myeloablative (Flu 1 Bu or
Cy1 Bu) versus nonmyeloablative (Flu 1 TBI) condi-
tioning prior to allo-PBSCT. Patients are stratified by
transplant center (FHCRC versus other), diagnosis
(AML versus MDS), donor (MRD versus URD), and
etiology (primary versus treatment related).
The Cooperative German Transplant Study
Group has sponsored 2 single center, phase III, rando-
mized, prospective studies comparing nonmyeloabla-
tive (Flu 1 TBI, 8 Gy) versus myeloablative (Cy 1
TBI, 12 Gy) conditioning prior to allo-SCT in adult
(18-60 years) AML patients in CR1 (Protocol ID:
9005-2005) or in CR2 (Protocol ID: AML_CR2_
Allo_HSCT).
The Hoˆpital Saint Antoine in France has spon-
sored a multicenter, phase III, randomized, prospec-
tive study (Protocol ID: P040420) of adult (35-55
years) patients with AML, comparing myeloablative
(Cy 1 TBI) versus nonmyeloablative (Flu 1 TBI,
2Gy) conditioning prior to allo-SCT.
The Technische Universitaet Dresden, Germany,
has sponsored a single center, phase III, randomized,
prospective study (AML2003, Protocol ID: MK1-95)
investigating standard versus intensified therapy for
adult (16-60 years) AML patients prior to allo-
HSCT. In the first 8 months of the trial, 107 AML pa-
tients with a median age of 48 years (17-60 years) were
recruited, 57 of whom were randomized to the inten-
sive treatment arm [143].
RIC allo-HSCT versus chemotherapy. The Cooperative
German Transplant Study Group (Protocol ID:
TRALG1/02) has sponsored a multicenter, prospec-
tive study of older adult (51-70 years) AML patients
in a donor versus no donor design comparing allo-
HSCT with RIC versus traditional chemotherapy.
G-CSF-mobilized PBSC versus BM allo-HSCT. The
National Marrow Donor Program (NMDP) and theNational Institutes of Health (NIH) have sponsored
a phase III randomized, multicenter, prospective trial
(Protocol ID: BMTCTN-0201) of adult (#66 years)
patients with hematologic malignancies (AML, ALL,
CML, MDS, myeloproliferative diseases, and therapy-
related AML or MDS), comparing survival outcomes
after granulocyte colony stimulating factor (G-CSF)-
mobilized PBSCT versus BMT fromHLA-compatible
unrelated donors.
Nonmyeloablative allo-HSCT in older patients. The
CALGB has sponsored a phase II trial (Protocol ID:
CALGB-100103) studying the efficacy of a RIC regi-
men of Flu1 Bu followed by allo-HSCT to treat older
adult (60-74 years) patients with AML in CR1.
STRENGTHS/LIMITATIONS AND DISCUSSION
The strengths of this systematic evidence-based re-
view are the details conveyed in the text about each
study’s design, the presentation of outcomes in sum-
mary tables for each major section, and the treatment
recommendations made by the adult AML expert
panel. A limitation of this systematic evidence-based
review is the inclusion of only published data, specifi-
cally peer-reviewed articles published since 1990. Un-
published data can represent ‘‘negative’’ findings that
could lead to publication bias; however, the inclusion
of high-quality, peer-reviewed publicly available data
was of paramount importance. Also excluded were
data published in abstract form because abstracts do
not adequately convey the full details of the study de-
sign or patient characteristics to meet evidence-based
criteria for inclusion in systematic reviews, nor for
making a true assessment of the widespread applicabil-
ity or impact of the treatment outside the scope of the
trial.
A limitation of the studies included in this review is
the inability to provide level ‘‘1’’ evidence for allo-
HSCT trials because of the low rate of patients
allocated to the allo-HSCT arm who would actually
receive the assigned treatment (approximately 35%
of patients have a matched-related donor [144]).
Therefore, trials that biologically allocate patients to
allo-HSCT based on donor availability have level
‘‘2’’ as their highest evidence grade.
Other study-specific limitations that affect the
quality of this systematic evidence-based review in-
clude the variability in reporting patient characteristics
pre-HSCT, changing treatment modalities over time,
and the paucity of RCT data on sufficiently large
patient populations. The success of most therapies is
affected by cytogenetic risk, which is either not re-
ported, not collected, or missing on too many patients.
Chemotherapy regimens, HLA typing techniques,
pre-HSCT treatment regimens, stem cell sources,
and post-HSCT supportive care have changed consid-
erably over the 17 years of trials included in this review.
174 D. M. Oliansky et al.The clinical research process is lengthy, making the
data from many of these studies outmoded at the
time of publication. RCT data were lacking in many
areas of this review, leading to several treatment rec-
ommendations based on small prospective studies
and/or large retrospective registry reports.
To address some of these limitations, the authors
recommend methodology standardization, including
use of consistent study designs, endpoint definitions,
and reporting of study results. Multicenter random-
ized phase III comparative trials with large enroll-
ments and high statistical power are required to
advance the field more constructively than single insti-
tution phase II trials with 1 treatment arm, or retro-
spective multicenter or registry studies. Much of
today’s therapies for cancer result from the random-
ized clinical trial process. It is currently estimated
that\5% of adult cancer patients who are eligible to
participate in clinical trials actually enroll in a trial.
The authors acknowledge the importance of removing
barriers to participation in clinical trials, which may
include patients’ reluctance to be randomized, lack
of patient access to clinical trials (eg, geographic,
transportation, cultural), financial restraints (no orincomplete insurance coverage for trial expenses),
stringent trial eligibility criteria, and reluctance of
community physicians to refer patients for clinical trial
participation.
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4-HC 4-hydroperoxcyclophosphamide
ABMTR Autologous Blood and Marrow Trans-
plant Registry
Allo Allogeneic
ALP Acute leukemia protocol
AML acute myelogenous leukemia
AMSA Amsacrine
APL acute promyelocytic leukemia
Ara-C Cytarabine
Auto autologous
BM bone marrow
BMT bone marrow transplantation
Bu Busulfan
CALGB Cancer and Leukemia Group B
CI (95%) confidence interval
CIBMTR Center for International Blood and
Marrow Research
CMV cytomegalovirus
CNS central nervous system
CR complete remission
CR1 first complete remission
CR2 second complete remission
Cy cyclophosphamide
DFS disease-free survival
DLI donor lymphocyte infusion
DS Down syndrome
DNR Daunorubicin
DOX Doxorubicin
EBMT European Group for Blood and Marrow
Transplant
ECOG Eastern Cooperative Oncology Group
EFS event-free survival
EMD extramedullary disease
EORTC European Organization of Research and
Treatment of Cancer
FAB French-American-Britishmorphology
classification
GAMLCG German AML Cooperative Group
GEGMO Groupe d’Etudes de la Greffe de Moelle
Ouest
GIMEMA Gruppo Italiano Malattie Ematologiche
Maligne dell’Adulto
GOELAM Groupe Ouest Est Leucemies Aigue¨s
Myeloblastiques
HiDAC high-dose Ara-C
HLA human leukocyte antigen
HOVON (Dutch-Belgian)Haemato-OncologyCo-
operative Group
HR high-risk and hazard ratio
HSCT hematopoietic stem cell transplantation
IBMTR International Bone Marrow Transplant
Registry
ICC intensive consolidation chemotherapy
IDR Idarubicin
ITT intention to treat
LFS leukemia-free survival
MDS myelodysplastic syndrome
Mel Melphalan
MITO Mitozantrone
MRC Medical Research Council
The Role of Cytotoxic Therapy with HSCT 175MRD matched-related donor
MUD matched-unrelated donor
OS overall survival
PBSC peripheral blood stem cells
PBSCT peripheral blood stem cell transplanta-
tion
PMRD partially matched related donor
QOL quality of life
RCT randomized controlled trial
RFS relapse-free survival
RR relative risk
RBZ Rubidazone
SAKK SwissGroup forClinicalCancerResearch
SCT stem cell transplantation
SFGM Societe Franc¸aise de Greffe de Moelle
SR standard risk
SWOG Southwest Oncology Group
SWPS survival-weighted psychometric scores
TBI total body irradiation
TG Thioguanine
TRM treatment-related mortality
URD unrelated donor
VP-16 Etoposide
WBC white blood cell
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